{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,13]],"date-time":"2026-09-13T23:57:56Z","timestamp":1789343876577,"version":"build-2803163510"},"reference-count":319,"publisher":"MDPI AG","issue":"10","license":[{"start":{"date-parts":[[2025,5,14]],"date-time":"2025-05-14T00:00:00Z","timestamp":1747180800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"Ministry of Education","award":["RS-2023-00241461"],"award-info":[{"award-number":["RS-2023-00241461"]}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["IJMS"],"abstract":"<jats:p>Neurological disorders, encompassing neurodegenerative and neuroinflammatory conditions, present significant public health and clinical challenges. Recent research has elucidated the pivotal role of various enzymes in the onset and progression of these disorders. This review explores the therapeutic potential of targeting these enzymes with natural and synthetic molecules. Key enzymes, including acetylcholinesterase, monoamine oxidase, beta-secretase, tau kinases, caspases, and cyclooxygenase-2, are implicated in diseases such as Alzheimer\u2019s disease, Parkinson\u2019s disease, and multiple sclerosis. Modulating these enzymes can alleviate symptoms, slow disease progression, or reverse pathological changes. Natural molecules derived from plants, microbes, seaweeds, and animals have long been noted for their therapeutic potential. Their ability to interact with specific enzymes with high specificity and minimal side effects makes them promising candidates for treatment. These natural agents provide a foundation for developing targeted therapies with improved safety profiles. Simultaneously, the development of synthetic chemistry has resulted in molecules designed to inhibit neurodegenerative enzymes with precision. This review examines the progress in creating small molecules, peptides, and enzyme inhibitors through sophisticated drug design techniques. It evaluates the efficacy, safety, and mechanisms of these synthetic agents, highlighting their potential for clinical application. The review offers a comprehensive overview of recent advancements in enzyme-targeted therapies for neurological disorders, covering both natural and synthetic molecules investigated in preclinical and clinical settings. It discusses the mechanisms through which these molecules exert their effects, the challenges faced in their development, and future research directions. By synthesizing current knowledge, this paper aims to illuminate the potential of enzyme-targeted interventions in managing neurological disorders, showcasing both the promise and limitations of these approaches.<\/jats:p>","DOI":"10.3390\/ijms26104707","type":"journal-article","created":{"date-parts":[[2025,5,14]],"date-time":"2025-05-14T10:06:52Z","timestamp":1747217212000},"page":"4707","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":9,"title":["Alleviation of Neurological Disorders by Targeting Neurodegenerative-Associated Enzymes: Natural and Synthetic Molecules"],"prefix":"10.3390","volume":"26","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-4049-102X","authenticated-orcid":false,"given":"Alka Ashok","family":"Singh","sequence":"first","affiliation":[{"name":"Department of Life Sciences, Yeungnam University, Gyeongsan 38541, Republic of Korea"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4902-3188","authenticated-orcid":false,"given":"Fazlurrahman","family":"Khan","sequence":"additional","affiliation":[{"name":"Ocean and Fisheries Development International Cooperation Institute, Pukyong National University, Busan 48513, Republic of Korea"},{"name":"International Graduate Program of Fisheries Science, Pukyong National University, Busan 48513, Republic of Korea"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Minseok","family":"Song","sequence":"additional","affiliation":[{"name":"Department of Life Sciences, Yeungnam University, Gyeongsan 38541, Republic of Korea"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2025,5,14]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","unstructured":"Ningrum, D.N.A., and Kung, W.-M. (2023). Challenges and perspectives of neurological disorders. Brain Sci., 13.","DOI":"10.3390\/brainsci13040676"},{"key":"ref_2","doi-asserted-by":"crossref","unstructured":"Giri, P.M., Banerjee, A., Ghosal, A., and Layek, B. (2024). Neuroinflammation in neurodegenerative disorders: Current knowledge and therapeutic implications. Int. J. Mol. Sci., 25.","DOI":"10.3390\/ijms25073995"},{"key":"ref_3","doi-asserted-by":"crossref","unstructured":"Kim, M.E., and Lee, J.S. (2024). Mechanisms and Emerging Regulators of Neuroinflammation: Exploring New Therapeutic Strategies for Neurological Disorders. Curr. Issues Mol. Biol., 47.","DOI":"10.3390\/cimb47010008"},{"key":"ref_4","first-page":"621","article-title":"Neuroinflamm-aging and neurodegenerative diseases: An overview","volume":"10","author":"Pizza","year":"2011","journal-title":"CNS Neurol. Disord.-Drug Targets (Former. Curr. Drug Targets-CNS Neurol. Disord.)"},{"key":"ref_5","doi-asserted-by":"crossref","unstructured":"Adamu, A., Li, S., Gao, F., and Xue, G. (2024). The role of neuroinflammation in neurodegenerative diseases: Current understanding and future therapeutic targets. Front. Aging Neurosci., 16.","DOI":"10.3389\/fnagi.2024.1347987"},{"key":"ref_6","doi-asserted-by":"crossref","unstructured":"Rauf, A., Badoni, H., Abu-Izneid, T., Olatunde, A., Rahman, M.M., Painuli, S., Semwal, P., Wilairatana, P., and Mubarak, M.S. (2022). Neuroinflammatory markers: Key indicators in the pathology of neurodegenerative diseases. Molecules, 27.","DOI":"10.3390\/molecules27103194"},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1111\/imm.12233","article-title":"Inflammation in neurodegenerative diseases\u2013an update","volume":"142","author":"Amor","year":"2014","journal-title":"Immunology"},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"204","DOI":"10.1111\/imm.12922","article-title":"Inflammation in CNS neurodegenerative diseases","volume":"154","author":"Stephenson","year":"2018","journal-title":"Immunology"},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"466","DOI":"10.26452\/ijrps.v12i1.4092","article-title":"Role of Enzymes in Causing Neurological Disorders","volume":"12","author":"Vysakh","year":"2021","journal-title":"Int. J. Res. Pharm. Sci."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"e02506882311325","DOI":"10.2174\/0102506882311325240815105251","article-title":"Focusing on Enzyme Suppression in Neurodegenerative Disorders: Promising Approaches for Therapeutic Measures","volume":"5","author":"Kumar","year":"2024","journal-title":"New Emir. Med. J."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"316","DOI":"10.2174\/1389450119666180820104723","article-title":"Potential enzymatic targets in Alzheimer\u2019s: A comprehensive review","volume":"20","author":"Alam","year":"2019","journal-title":"Curr. Drug Targets"},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"102033","DOI":"10.1016\/j.arr.2023.102033","article-title":"The neurobiology and therapeutic potential of multi-targeting \u03b2-secretase, glycogen synthase kinase 3\u03b2 and acetylcholinesterase in Alzheimer\u2019s disease","volume":"90","author":"Fronza","year":"2023","journal-title":"Ageing Res. Rev."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"610","DOI":"10.2174\/1871527320666210811160007","article-title":"Strategic approaches to target the enzymes using natural compounds for the management of Alzheimer\u2019s disease: A review","volume":"21","author":"Ahmad","year":"2022","journal-title":"CNS Neurol. Disord.-Drug Targets-CNS Neurol. Disord."},{"key":"ref_14","doi-asserted-by":"crossref","unstructured":"Walczak-Nowicka, \u0141.J., and Herbet, M. (2021). Acetylcholinesterase inhibitors in the treatment of neurodegenerative diseases and the role of acetylcholinesterase in their pathogenesis. Int. J. Mol. Sci., 22.","DOI":"10.3390\/ijms22179290"},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1358\/dot.2003.39.1.740206","article-title":"The role of acetylcholinesterase in the pathogenesis of Alzheimer\u2019s disease","volume":"39","author":"Rees","year":"2003","journal-title":"Drugs Today"},{"key":"ref_16","doi-asserted-by":"crossref","unstructured":"Garc\u00eda-Ayll\u00f3n, M.-S., Small, D.H., Avila, J., and S\u00e1ez-Valero, J. (2011). Revisiting the role of acetylcholinesterase in Alzheimer\u2019s disease: Cross-talk with P-tau and \u03b2-amyloid. Front. Mol. Neurosci., 4.","DOI":"10.3389\/fnmol.2011.00022"},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"S32","DOI":"10.1212\/WNL.63.7_suppl_2.S32","article-title":"A review of the mechanisms and role of monoamine oxidase inhibitors in Parkinson\u2019s disease","volume":"63","author":"Youdim","year":"2004","journal-title":"Neurology"},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"87","DOI":"10.2174\/1389450117666151209123402","article-title":"A perspective on monoamine oxidase enzyme as drug target: Challenges and opportunities","volume":"18","author":"Kumar","year":"2017","journal-title":"Curr. Drug Targets"},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"1487","DOI":"10.1002\/cbic.201800813","article-title":"Structure-Based Specific Detection and Inhibition of Monoamine Oxidases and Their Applications in Central Nervous System Diseases","volume":"20","author":"Shi","year":"2019","journal-title":"ChemBioChem"},{"key":"ref_20","doi-asserted-by":"crossref","unstructured":"Nam, M.-H., Sa, M., Ju, Y.H., Park, M.G., and Lee, C.J. (2022). Revisiting the role of astrocytic MAOB in Parkinson\u2019s disease. Int. J. Mol. Sci., 23.","DOI":"10.3390\/ijms23084453"},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"4890","DOI":"10.1073\/pnas.94.10.4890","article-title":"Parkinson disease: A new link between monoamine oxidase and mitochondrial electron flow","volume":"94","author":"Cohen","year":"1997","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"71","DOI":"10.3233\/JAD-220873","article-title":"The role of caspases in Alzheimer\u2019s disease: Pathophysiology implications and pharmacologic modulation","volume":"91","author":"Khezri","year":"2023","journal-title":"J. Alzheimer\u2019s Dis."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1093\/jnen\/64.2.104","article-title":"The role of caspase cleavage of tau in Alzheimer disease neuropathology","volume":"64","author":"Cotman","year":"2005","journal-title":"J. Neuropathol. Exp. Neurol."},{"key":"ref_24","first-page":"48","article-title":"Caspase cleavage of the amyloid precursor protein is prevented after overexpression of bcl-2 in a triple transgenic mouse model of Alzheimer\u2019s disease","volume":"1","author":"Kumasaka","year":"2009","journal-title":"Int. J. Physiol. Pathophysiol. Pharmacol."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"549","DOI":"10.1358\/dnp.2002.15.9.740233","article-title":"Caspase activation in the Alzheimer\u2019s disease brain: Tortuous and torturous","volume":"15","author":"Rohn","year":"2002","journal-title":"Drug News Perspect."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"1679","DOI":"10.1038\/cdd.2011.107","article-title":"The executioners sing a new song: Killer caspases activate microglia","volume":"18","author":"Venero","year":"2011","journal-title":"Cell Death Differ."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1016\/j.brainresrev.2006.02.002","article-title":"Cyclooxygenases, lipoxygenases, and epoxygenases in CNS: Their role and involvement in neurological disorders","volume":"52","author":"Phillis","year":"2006","journal-title":"Brain Res. Rev."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"901","DOI":"10.1093\/jnen\/63.9.901","article-title":"Cyclooxygenase-2 (COX-2) in inflammatory and degenerative brain diseases","volume":"63","author":"Minghetti","year":"2004","journal-title":"J. Neuropathol. Exp. Neurol."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1016\/j.biochi.2010.09.009","article-title":"Targeting cyclooxygenases-1 and -2 in neuroinflammation: Therapeutic implications","volume":"93","author":"Bosetti","year":"2011","journal-title":"Biochimie"},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"1443","DOI":"10.2174\/138161208784480144","article-title":"Cyclooxygenase-2 in synaptic signaling","volume":"14","author":"Yang","year":"2008","journal-title":"Curr. Pharm. Des."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1016\/j.jneuroim.2003.12.021","article-title":"Inflammatory cell expression of cyclooxygenase-2 in the multiple sclerosis lesion","volume":"149","author":"Rose","year":"2004","journal-title":"J. Neuroimmunol."},{"key":"ref_32","doi-asserted-by":"crossref","unstructured":"Palumbo, S. (2017). Pathogenesis and progression of multiple sclerosis: The role of arachidonic acid-mediated neuroinflammation. Exon Publ., 111\u2013123.","DOI":"10.15586\/codon.multiplesclerosis.2017.ch7"},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1016\/j.plefa.2013.08.008","article-title":"Alterations of brain eicosanoid synthetic pathway in multiple sclerosis and in animal models of demyelination: Role of cyclooxygenase-2","volume":"89","author":"Palumbo","year":"2013","journal-title":"Prostaglandins Leukot. Essent. Fat. Acids"},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"174","DOI":"10.1016\/j.tips.2009.01.002","article-title":"The distinct roles of cyclooxygenase-1 and-2 in neuroinflammation: Implications for translational research","volume":"30","author":"Choi","year":"2009","journal-title":"Trends Pharmacol. Sci."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"1323","DOI":"10.1021\/acs.chemrev.8b00201","article-title":"Targeting metalloenzymes for therapeutic intervention","volume":"119","author":"Chen","year":"2018","journal-title":"Chem. Rev."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"113492","DOI":"10.1016\/j.ejmech.2021.113492","article-title":"Dual-target compounds for Alzheimer\u2019s disease: Natural and synthetic AChE and BACE-1 dual-inhibitors and their structure-activity relationship (SAR)","volume":"221","author":"Ferreira","year":"2021","journal-title":"Eur. J. Med. Chem."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"437","DOI":"10.4103\/1673-5374.245463","article-title":"Multitarget therapeutic strategies for Alzheimer\u2019s disease","volume":"14","author":"Ibrahim","year":"2019","journal-title":"Neural Regen. Res."},{"key":"ref_38","doi-asserted-by":"crossref","unstructured":"Wang, S., Kong, X., Chen, Z., Wang, G., Zhang, J., and Wang, J. (2022). Role of natural compounds and target enzymes in the treatment of Alzheimer\u2019s disease. Molecules, 27.","DOI":"10.3390\/molecules27134175"},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"264","DOI":"10.2174\/1568026619666190128125912","article-title":"Target enzyme in Alzheimer\u2019s disease: Acetylcholinesterase inhibitors","volume":"19","author":"Saxena","year":"2019","journal-title":"Curr. Top. Med. Chem."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1016\/j.arr.2014.03.008","article-title":"Alzheimer\u2019s disease, enzyme targets and drug discovery struggles: From natural products to drug prototypes","volume":"15","author":"Silva","year":"2014","journal-title":"Ageing Res. Rev."},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"700","DOI":"10.1016\/j.ijbiomac.2017.01.076","article-title":"Management of Alzheimer\u2019s disease-An insight of the enzymatic and other novel potential targets","volume":"97","author":"Islam","year":"2017","journal-title":"Int. J. Biol. Macromol."},{"key":"ref_42","doi-asserted-by":"crossref","unstructured":"Rahman, M.H., Bajgai, J., Fadriquela, A., Sharma, S., Trinh, T.T., Akter, R., Jeong, Y.J., Goh, S.H., Kim, C.-S., and Lee, K.-J. (2021). Therapeutic potential of natural products in treating neurodegenerative disorders and their future prospects and challenges. Molecules, 26.","DOI":"10.3390\/molecules26175327"},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"3574012","DOI":"10.1155\/2017\/3574012","article-title":"Plants-derived neuroprotective agents: Cutting the cycle of cell death through multiple mechanisms","volume":"2017","author":"Elufioye","year":"2017","journal-title":"Evid.-Based Complement. Altern. Med."},{"key":"ref_44","doi-asserted-by":"crossref","unstructured":"Hussain, G., Rasul, A., Anwar, H., Aziz, N., Razzaq, A., Wei, W., Ali, M., Li, J., and Li, X. (2018). Role of plant derived alkaloids and their mechanism in neurodegenerative disorders. Int. J. Biol. Sci., 14.","DOI":"10.7150\/ijbs.23247"},{"key":"ref_45","doi-asserted-by":"crossref","unstructured":"Kong, Y.R., Tay, K.C., Su, Y.X., Wong, C.K., Tan, W.N., and Khaw, K.Y. (2021). Potential of naturally derived alkaloids as multi-targeted therapeutic agents for neurodegenerative diseases. Molecules, 26.","DOI":"10.3390\/molecules26030728"},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"102271","DOI":"10.1016\/j.arr.2024.102271","article-title":"Sonic hedgehog signalling pathway contributes in age-related disorders and Alzheimer\u2019s disease","volume":"96","author":"Parashar","year":"2024","journal-title":"Ageing Res. Rev."},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"529","DOI":"10.2174\/1567205016666190315093520","article-title":"Mitigating Alzheimer\u2019s disease with natural polyphenols: A review","volume":"16","author":"Gaudreault","year":"2019","journal-title":"Curr. Alzheimer Res."},{"key":"ref_48","doi-asserted-by":"crossref","unstructured":"Andrade, S., Ramalho, M.J., Loureiro, J.A., and Pereira, M.d.C. (2019). Natural compounds for Alzheimer\u2019s disease therapy: A systematic review of preclinical and clinical studies. Int. J. Mol. Sci., 20.","DOI":"10.3390\/ijms20092313"},{"key":"ref_49","doi-asserted-by":"crossref","unstructured":"Stacchiotti, A., and Corsetti, G. (2020). Natural compounds and autophagy: Allies against neurodegeneration. Front. Cell Dev. Biol., 8.","DOI":"10.3389\/fcell.2020.555409"},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1016\/j.phrs.2017.11.028","article-title":"Nutraceuticals: An emerging therapeutic approach against the pathogenesis of Alzheimer\u2019s disease","volume":"129","author":"Sadhukhan","year":"2018","journal-title":"Pharmacol. Res."},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"e202300705","DOI":"10.1002\/cmdc.202300705","article-title":"Current small molecule\u2013based medicinal chemistry approaches for neurodegeneration therapeutics","volume":"19","author":"Sanghai","year":"2024","journal-title":"ChemMedChem"},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"1662","DOI":"10.2174\/09298673113209990112","article-title":"Rationally designed multi-targeted agents against neurodegenerative diseases","volume":"20","author":"Geldenhuys","year":"2013","journal-title":"Curr. Med. Chem."},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"979","DOI":"10.1002\/bies.201400094","article-title":"Synthetic biology and therapeutic strategies for the degenerating brain: Synthetic biology approaches can transform classical cell and gene therapies, to provide new cures for neurodegenerative diseases","volume":"36","author":"Isalan","year":"2014","journal-title":"Bioessays"},{"key":"ref_54","unstructured":"Ryan, P. (2020). An Investigation Into Novel Molecular Strategies Targeting Neurodegenerative Diseases. [Ph.D. Thesis, Griffith University]."},{"key":"ref_55","doi-asserted-by":"crossref","unstructured":"Coimbra, J.R., Marques, D.F., Baptista, S.J., Pereira, C.M., Moreira, P.I., Dinis, T.C., Santos, A.E., and Salvador, J.A. (2018). Highlights in BACE1 inhibitors for Alzheimer\u2019s disease treatment. Front. Chem., 6.","DOI":"10.3389\/fchem.2018.00178"},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"1195","DOI":"10.2174\/1568026620666200416091623","article-title":"Recent studies on design and development of drugs against Alzheimer\u2019s disease (AD) based on inhibition of BACE-1 and other AD-causative agents","volume":"20","author":"Gupta","year":"2020","journal-title":"Curr. Top. Med. Chem."},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"1811","DOI":"10.2174\/092986706777452489","article-title":"Development of BACE1 inhibitors for Alzheimer\u2019s disease","volume":"13","author":"Guo","year":"2006","journal-title":"Curr. Med. Chem."},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"1806","DOI":"10.2174\/092986709788186174","article-title":"Progress in the development of nonpeptidomimetic BACE 1 inhibitors for Alzheimer\u2019s disease","volume":"16","author":"Huang","year":"2009","journal-title":"Curr. Med. Chem."},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"6765","DOI":"10.1039\/C3CS60460H","article-title":"BACE1 (\u03b2-secretase) inhibitors for the treatment of Alzheimer\u2019s disease","volume":"43","author":"Ghosh","year":"2014","journal-title":"Chem. Soc. Rev."},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"464","DOI":"10.1038\/nrd2111","article-title":"Untangling tau hyperphosphorylation in drug design for neurodegenerative diseases","volume":"6","author":"Mazanetz","year":"2007","journal-title":"Nat. Rev. Drug Discov."},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"339","DOI":"10.1002\/med.21622","article-title":"BACE1 inhibitors: Current status and future directions in treating Alzheimer\u2019s disease","volume":"40","author":"Abdin","year":"2020","journal-title":"Med. Res. Rev."},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"619","DOI":"10.1021\/acs.jmedchem.7b00393","article-title":"BACE-1 inhibitors: From recent single-target molecules to multitarget compounds for Alzheimer\u2019s disease: Miniperspective","volume":"61","author":"Prati","year":"2018","journal-title":"J. Med. Chem."},{"key":"ref_63","doi-asserted-by":"crossref","first-page":"1725","DOI":"10.1517\/14728222.2015.1071794","article-title":"Role of sphingomyelinases in neurological disorders","volume":"19","author":"Ong","year":"2015","journal-title":"Expert Opin. Ther. Targets"},{"key":"ref_64","doi-asserted-by":"crossref","first-page":"1671","DOI":"10.1021\/acschembio.0c00311","article-title":"Dual Neutral Sphingomyelinase-2\/Acetylcholinesterase Inhibitors for the Treatment of Alzheimer\u2019s Disease","volume":"15","author":"Bilousova","year":"2020","journal-title":"ACS Chem. Biol."},{"key":"ref_65","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1139\/o03-091","article-title":"Acid and neutral sphingomyelinases: Roles and mechanisms of regulation","volume":"82","author":"Marchesini","year":"2004","journal-title":"Biochem. Cell Biol."},{"key":"ref_66","doi-asserted-by":"crossref","first-page":"5895","DOI":"10.1073\/pnas.97.11.5895","article-title":"Cloning and characterization of the mammalian brain-specific, Mg2+-dependent neutral sphingomyelinase","volume":"97","author":"Hofmann","year":"2000","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_67","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/1742-2094-10-109","article-title":"Early activation of nSMase2\/ceramide pathway in astrocytes is involved in ischemia-associated neuronal damage via inflammation in rat hippocampi","volume":"10","author":"Gu","year":"2013","journal-title":"J. NeuroInflamm."},{"key":"ref_68","doi-asserted-by":"crossref","first-page":"398","DOI":"10.1016\/j.neurobiolaging.2008.05.010","article-title":"Deregulation of sphingolipid metabolism in Alzheimer\u2019s disease","volume":"31","author":"He","year":"2010","journal-title":"Neurobiol. Aging"},{"key":"ref_69","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1016\/j.freeradbiomed.2014.07.012","article-title":"Oxidized LDL lipids increase \u03b2-amyloid production by SH-SY5Y cells through glutathione depletion and lipid raft formation","volume":"75","author":"Dias","year":"2014","journal-title":"Free Radic. Biol. Med."},{"key":"ref_70","doi-asserted-by":"crossref","first-page":"1551","DOI":"10.1084\/jem.20132451","article-title":"Acid sphingomyelinase modulates the autophagic process by controlling lysosomal biogenesis in Alzheimer\u2019s disease","volume":"211","author":"Lee","year":"2014","journal-title":"J. Exp. Med."},{"key":"ref_71","doi-asserted-by":"crossref","unstructured":"Fonteh, A.N., Ormseth, C., Chiang, J., Cipolla, M., Arakaki, X., and Harrington, M.G. (2015). Sphingolipid metabolism correlates with cerebrospinal fluid Beta amyloid levels in Alzheimer\u2019s disease. PLoS ONE, 10.","DOI":"10.1371\/journal.pone.0125597"},{"key":"ref_72","doi-asserted-by":"crossref","first-page":"6647","DOI":"10.1073\/pnas.88.15.6647","article-title":"Cholinesterase-like domains in enzymes and structural proteins: Functional and evolutionary relationships and identification of a catalytically essential aspartic acid","volume":"88","author":"Krejci","year":"1991","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_73","doi-asserted-by":"crossref","first-page":"1961","DOI":"10.1016\/S0047-6374(01)00309-8","article-title":"Acetylcholinesterase in Alzheimer\u2019s disease","volume":"122","author":"Talesa","year":"2001","journal-title":"Mech. Ageing Dev."},{"key":"ref_74","doi-asserted-by":"crossref","first-page":"1600","DOI":"10.1046\/j.1471-4159.1999.721600.x","article-title":"Molecular isoform distribution and glycosylation of acetylcholinesterase are altered in brain and cerebrospinal fluid of patients with Alzheimer\u2019s disease","volume":"72","author":"Sberna","year":"1999","journal-title":"J. Neurochem."},{"key":"ref_75","doi-asserted-by":"crossref","first-page":"26731","DOI":"10.4088\/PCC.12r01412","article-title":"A review of butyrylcholinesterase as a therapeutic target in the treatment of Alzheimer\u2019s disease","volume":"15","author":"Nordberg","year":"2013","journal-title":"Prim. Care Companion CNS Disord."},{"key":"ref_76","doi-asserted-by":"crossref","first-page":"1852","DOI":"10.1212\/01.WNL.0000068336.84399.9E","article-title":"Butyrylcholinesterase and progression of cognitive deficits in dementia with Lewy bodies","volume":"60","author":"Perry","year":"2003","journal-title":"Neurology"},{"key":"ref_77","doi-asserted-by":"crossref","first-page":"116810","DOI":"10.1016\/j.ejmech.2024.116810","article-title":"Dual-Target Inhibitors Based on Acetylcholinesterase: Novel Agents for Alzheimer\u2019s Disease","volume":"279","author":"Zhao","year":"2024","journal-title":"Eur. J. Med. Chem."},{"key":"ref_78","doi-asserted-by":"crossref","first-page":"50","DOI":"10.2174\/0115672050306008240321034006","article-title":"Current progress on central cholinergic receptors as therapeutic targets for Alzheimer\u2019s disease","volume":"21","author":"Nagori","year":"2024","journal-title":"Curr. Alzheimer Res."},{"key":"ref_79","first-page":"450","article-title":"Acetylcholinesterase: A versatile template to coin potent modulators of multiple therapeutic targets","volume":"57","author":"Luque","year":"2024","journal-title":"Acc. Chem. Res."},{"key":"ref_80","first-page":"741","article-title":"Acetylcholinesterase inhibitors reduce brain and blood interleukin-1\u03b2 production","volume":"57","author":"Pollak","year":"2005","journal-title":"Ann. Neurol. Off. J. Am. Neurol. Assoc. Child Neurol. Soc."},{"key":"ref_81","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1016\/j.exger.2004.12.003","article-title":"Acetylcholinesterase inhibitors effects on oncostatin-M, interleukin-1\u03b2 and interleukin-6 release from lymphocytes of Alzheimer\u2019s disease patients","volume":"40","author":"Reale","year":"2005","journal-title":"Exp. Gerontol."},{"key":"ref_82","doi-asserted-by":"crossref","first-page":"162","DOI":"10.1016\/j.jneuroim.2003.11.003","article-title":"Treatment with an acetylcholinesterase inhibitor in Alzheimer patients modulates the expression and production of the pro-inflammatory and anti-inflammatory cytokines","volume":"148","author":"Reale","year":"2004","journal-title":"J. Neuroimmunol."},{"key":"ref_83","doi-asserted-by":"crossref","first-page":"138","DOI":"10.1097\/JCP.0000000000000840","article-title":"Acetyl cholinesterase inhibitors and cell-derived peripheral inflammatory cytokines in early stages of Alzheimer\u2019s disease","volume":"38","author":"Kokras","year":"2018","journal-title":"J. Clin. Psychopharmacol."},{"key":"ref_84","doi-asserted-by":"crossref","unstructured":"Kim, J., Lee, H.-j., Park, S.K., Park, J.-H., Jeong, H.-R., Lee, S., Lee, H., Seol, E., and Hoe, H.-S. (2021). Donepezil regulates LPS and A\u03b2-stimulated neuroinflammation through MAPK\/NLRP3 inflammasome\/STAT3 signaling. Int. J. Mol. Sci., 22.","DOI":"10.3390\/ijms221910637"},{"key":"ref_85","doi-asserted-by":"crossref","first-page":"1983","DOI":"10.2174\/0929867043364784","article-title":"Structure and mechanism of monoamine oxidase","volume":"11","author":"Edmondson","year":"2004","journal-title":"Curr. Med. Chem."},{"key":"ref_86","doi-asserted-by":"crossref","first-page":"847","DOI":"10.2174\/1386207323666200402090557","article-title":"Treatment of parkinson\u2019s disease by MAO-B inhibitors, new therapies and future challenges-A mini-review","volume":"23","author":"Parambi","year":"2020","journal-title":"Comb. Chem. High Throughput Screen."},{"key":"ref_87","doi-asserted-by":"crossref","unstructured":"Riederer, P., and Laux, G. (2011). MAO-inhibitors in Parkinson\u2019s Disease. Exp. Neurobiol., 20.","DOI":"10.5607\/en.2011.20.1.1"},{"key":"ref_88","first-page":"477","article-title":"Monoamine oxidase-B inhibitors for the treatment of Parkinson\u2019s disease: Past, present, and future","volume":"12","author":"Tan","year":"2022","journal-title":"J. Park. Dis."},{"key":"ref_89","doi-asserted-by":"crossref","first-page":"6045","DOI":"10.2174\/0929867328666210203204710","article-title":"Monoamine oxidase-B (MAO-B) inhibitors in the treatment of Alzheimer\u2019s and Parkinson\u2019s disease","volume":"28","year":"2021","journal-title":"Curr. Med. Chem."},{"key":"ref_90","doi-asserted-by":"crossref","first-page":"723","DOI":"10.1007\/s00702-022-02465-w","article-title":"A critical appraisal of MAO-B inhibitors in the treatment of Parkinson\u2019s disease","volume":"129","author":"Jost","year":"2022","journal-title":"J. Neural Transm."},{"key":"ref_91","doi-asserted-by":"crossref","first-page":"745","DOI":"10.1016\/j.biopsych.2020.02.001","article-title":"The \u03b2-secretase BACE1 in Alzheimer\u2019s disease","volume":"89","author":"Hampel","year":"2021","journal-title":"Biol. Psychiatry"},{"key":"ref_92","doi-asserted-by":"crossref","first-page":"428","DOI":"10.1016\/j.biopsych.2016.12.023","article-title":"Beta-site amyloid precursor protein cleaving enzyme 1 inhibition impairs synaptic plasticity via seizure protein 6","volume":"83","author":"Zhu","year":"2018","journal-title":"Biol. Psychiatry"},{"key":"ref_93","doi-asserted-by":"crossref","first-page":"3639","DOI":"10.1523\/JNEUROSCI.4396-06.2007","article-title":"\u03b2-Site amyloid precursor protein cleaving enzyme 1 levels become elevated in neurons around amyloid plaques: Implications for Alzheimer\u2019s disease pathogenesis","volume":"27","author":"Zhao","year":"2007","journal-title":"J. Neurosci."},{"key":"ref_94","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1007\/s00401-013-1152-3","article-title":"The Alzheimer\u2019s \u03b2-secretase BACE1 localizes to normal presynaptic terminals and to dystrophic presynaptic terminals surrounding amyloid plaques","volume":"126","author":"Kandalepas","year":"2013","journal-title":"Acta Neuropathol."},{"key":"ref_95","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1007\/s00401-016-1558-9","article-title":"Presynaptic dystrophic neurites surrounding amyloid plaques are sites of microtubule disruption, BACE1 elevation, and increased A\u03b2 generation in Alzheimer\u2019s disease","volume":"132","author":"Sadleir","year":"2016","journal-title":"Acta Neuropathol."},{"key":"ref_96","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1016\/j.tins.2016.01.003","article-title":"BACE1 physiological functions may limit its use as therapeutic target for Alzheimer\u2019s disease","volume":"39","author":"Moechars","year":"2016","journal-title":"Trends Neurosci."},{"key":"ref_97","doi-asserted-by":"crossref","first-page":"441","DOI":"10.2174\/1567205011666140604122059","article-title":"The normal and pathologic roles of the Alzheimer\u2019s \u03b2-secretase, BACE1","volume":"11","author":"Kandalepas","year":"2014","journal-title":"Curr. Alzheimer Res."},{"key":"ref_98","doi-asserted-by":"crossref","unstructured":"Willem, M., Lammich, S., and Haass, C. (2009). Function, regulation and therapeutic properties of \u03b2-secretase (BACE1). Seminars in Cell & Developmental Biology, Academic Press.","DOI":"10.1016\/j.semcdb.2009.01.003"},{"key":"ref_99","doi-asserted-by":"crossref","first-page":"661","DOI":"10.1016\/0896-6273(95)90323-2","article-title":"Generation of amyloid \u03b2 protein from its precursor is sequence specific","volume":"14","author":"Citron","year":"1995","journal-title":"Neuron"},{"key":"ref_100","doi-asserted-by":"crossref","first-page":"537","DOI":"10.1038\/990114","article-title":"Purification and cloning of amyloid precursor protein \u03b2-secretase from human brain","volume":"402","author":"Sinha","year":"1999","journal-title":"Nature"},{"key":"ref_101","doi-asserted-by":"crossref","first-page":"500","DOI":"10.1038\/357500a0","article-title":"Targeting of cell-surface \u03b2-amyloid precursor protein to lysosomes: Alternative processing into amyloid-bearing fragments","volume":"357","author":"Haass","year":"1992","journal-title":"Nature"},{"key":"ref_102","doi-asserted-by":"crossref","first-page":"2240","DOI":"10.1038\/s41467-019-10152-w","article-title":"A\u03b234 is a BACE1-derived degradation intermediate associated with amyloid clearance and Alzheimer\u2019s disease progression","volume":"10","author":"Liebsch","year":"2019","journal-title":"Nat. Commun."},{"key":"ref_103","doi-asserted-by":"crossref","unstructured":"Ulku, I., Liebsch, F., Akerman, S.C., Schulz, J.F., Kulic, L., Hock, C., Pietrzik, C., Di Spiezio, A., Thinakaran, G., and Saftig, P. (2023). Mechanisms of amyloid-\u03b234 generation indicate a pivotal role for BACE1 in amyloid homeostasis. Sci. Rep., 13.","DOI":"10.1038\/s41598-023-28846-z"},{"key":"ref_104","doi-asserted-by":"crossref","first-page":"433","DOI":"10.3233\/JAD-215542","article-title":"Increased serum beta-secretase 1 activity is an early marker of Alzheimer\u2019s disease","volume":"87","author":"Nicsanu","year":"2022","journal-title":"J. Alzheimer\u2019s Dis."},{"key":"ref_105","doi-asserted-by":"crossref","first-page":"1858","DOI":"10.1073\/pnas.72.5.1858","article-title":"A protein factor essential for microtubule assembly","volume":"72","author":"Weingarten","year":"1975","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_106","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1038\/284353a0","article-title":"Changes in composition and activity of microtubule-associated proteins during brain development","volume":"284","author":"Mareck","year":"1980","journal-title":"Nature"},{"key":"ref_107","doi-asserted-by":"crossref","first-page":"4040","DOI":"10.1073\/pnas.83.11.4040","article-title":"Neurofibrillary tangles of Alzheimer disease share antigenic determinants with the axonal microtubule-associated protein tau (tau)","volume":"83","author":"Wood","year":"1986","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_108","doi-asserted-by":"crossref","first-page":"4913","DOI":"10.1073\/pnas.83.13.4913","article-title":"Abnormal phosphorylation of the microtubule-associated protein tau (tau) in Alzheimer cytoskeletal pathology","volume":"83","author":"Iqbal","year":"1986","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_109","doi-asserted-by":"crossref","first-page":"280","DOI":"10.1016\/j.bbadis.2004.06.017","article-title":"Tau phosphorylation: Physiological and pathological consequences","volume":"1739","author":"Stoothoff","year":"2005","journal-title":"Biochim. Et Biophys. Acta (BBA)-Mol. Basis Dis."},{"key":"ref_110","doi-asserted-by":"crossref","first-page":"1480","DOI":"10.1111\/j.1471-4159.2009.05882.x","article-title":"Developmental regulation of tau phosphorylation, tau kinases, and tau phosphatases","volume":"108","author":"Yu","year":"2009","journal-title":"J. Neurochem."},{"key":"ref_111","doi-asserted-by":"crossref","first-page":"519","DOI":"10.1016\/0896-6273(89)90210-9","article-title":"Multiple isoforms of human microtubule-associated protein tau: Sequences and localization in neurofibrillary tangles of Alzheimer\u2019s disease","volume":"3","author":"Goedert","year":"1989","journal-title":"Neuron"},{"key":"ref_112","doi-asserted-by":"crossref","first-page":"656","DOI":"10.2174\/156720510793611592","article-title":"Tau in Alzheimer disease and related tauopathies","volume":"7","author":"Iqbal","year":"2010","journal-title":"Curr. Alzheimer Res."},{"key":"ref_113","doi-asserted-by":"crossref","first-page":"2071","DOI":"10.1111\/j.1471-4159.1993.tb07444.x","article-title":"Developmental Changes in \u03c4 Phosphorylation: Fetal \u03c4 Is Transiently Phosphorylated in a Manner Similar to Paired Helical Filament-\u03c4 Characteristic of Alzheimer\u2019s Disease","volume":"61","author":"Brion","year":"1993","journal-title":"J. Neurochem."},{"key":"ref_114","doi-asserted-by":"crossref","first-page":"3","DOI":"10.2174\/1567205052772713","article-title":"Current advances on different kinases involved in tau phosphorylation, and implications in Alzheimer\u2019s disease and tauopathies","volume":"2","author":"Ferrer","year":"2005","journal-title":"Curr. Alzheimer Res."},{"key":"ref_115","doi-asserted-by":"crossref","first-page":"3429","DOI":"10.1111\/j.1460-9568.2007.05955.x","article-title":"Site-specific effects of tau phosphorylation on its microtubule assembly activity and self-aggregation","volume":"26","author":"Liu","year":"2007","journal-title":"Eur. J. Neurosci."},{"key":"ref_116","doi-asserted-by":"crossref","first-page":"3737","DOI":"10.1242\/jcs.113.21.3737","article-title":"C-terminal inhibition of tau assembly in vitro and in Alzheimer\u2019s disease","volume":"113","author":"Abraha","year":"2000","journal-title":"J. Cell Sci."},{"key":"ref_117","doi-asserted-by":"crossref","first-page":"1509","DOI":"10.1046\/j.1471-4159.2003.02287.x","article-title":"Pseudophosphorylation of tau protein alters its ability for self-aggregation","volume":"88","author":"Haase","year":"2004","journal-title":"J. Neurochem."},{"key":"ref_118","doi-asserted-by":"crossref","first-page":"40162","DOI":"10.1074\/jbc.M308243200","article-title":"\u03b2-Amyloid induces paired helical filament-like tau filaments in tissue culture","volume":"278","author":"Ferrari","year":"2003","journal-title":"J. Biol. Chem."},{"key":"ref_119","doi-asserted-by":"crossref","first-page":"1047","DOI":"10.1080\/13543776.2024.2397732","article-title":"Caspase inhibitors: A review on recently patented compounds (2016\u20132023)","volume":"34","author":"Kasana","year":"2024","journal-title":"Expert Opin. Ther. Pat."},{"key":"ref_120","doi-asserted-by":"crossref","unstructured":"Zhang, W., Zhu, C., Liao, Y., Zhou, M., Xu, W., and Zou, Z. (2024). Caspase-8 in inflammatory diseases: A potential therapeutic target. Cell. Mol. Biol. Lett., 29.","DOI":"10.1186\/s11658-024-00646-x"},{"key":"ref_121","doi-asserted-by":"crossref","first-page":"1352","DOI":"10.1016\/j.immuni.2019.05.020","article-title":"Caspases in cell death, inflammation, and disease","volume":"50","author":"Lamkanfi","year":"2019","journal-title":"Immunity"},{"key":"ref_122","doi-asserted-by":"crossref","first-page":"3916","DOI":"10.1038\/s41467-018-06449-x","article-title":"Caspase-1 inhibition alleviates cognitive impairment and neuropathology in an Alzheimer\u2019s disease mouse model","volume":"9","author":"Flores","year":"2018","journal-title":"Nat. Commun."},{"key":"ref_123","doi-asserted-by":"crossref","first-page":"3887","DOI":"10.1038\/s41467-019-11638-3","article-title":"Oligodendrocyte precursor cells present antigen and are cytotoxic targets in inflammatory demyelination","volume":"10","author":"Kirby","year":"2019","journal-title":"Nat. Commun."},{"key":"ref_124","doi-asserted-by":"crossref","first-page":"1231","DOI":"10.1007\/s11011-024-01389-6","article-title":"Alzheimer\u2019s disease: From early pathogenesis to novel therapeutic approaches","volume":"39","author":"Prajapati","year":"2024","journal-title":"Metab. Brain Dis."},{"key":"ref_125","doi-asserted-by":"crossref","first-page":"1173","DOI":"10.1172\/JCI72230","article-title":"Extracellular caspase-6 drives murine inflammatory pain via microglial TNF-\u03b1 secretion","volume":"124","author":"Berta","year":"2014","journal-title":"J. Clin. Investig."},{"key":"ref_126","doi-asserted-by":"crossref","first-page":"9383184","DOI":"10.1155\/2017\/9383184","article-title":"Unconventional Role of Caspase-6 in Spinal Microglia Activation and Chronic Pain","volume":"2017","author":"Berta","year":"2017","journal-title":"Mediat. Inflamm."},{"key":"ref_127","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1016\/j.bbi.2017.08.004","article-title":"Electroacupuncture inhibits NLRP3 inflammasome activation through CB2 receptors in inflammatory pain","volume":"67","author":"Gao","year":"2018","journal-title":"Brain Behav. Immun."},{"key":"ref_128","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1007\/s12264-017-0145-y","article-title":"Sex-dependent glial signaling in pathological pain: Distinct roles of spinal microglia and astrocytes","volume":"34","author":"Chen","year":"2018","journal-title":"Neurosci. Bull."},{"key":"ref_129","doi-asserted-by":"crossref","first-page":"933","DOI":"10.1084\/jem.185.5.933","article-title":"Expression of a dominant negative mutant of interleukin-1\u03b2 converting enzyme in transgenic mice prevents neuronal cell death induced by trophic factor withdrawal and ischemic brain injury","volume":"185","author":"Friedlander","year":"1997","journal-title":"J. Exp. Med."},{"key":"ref_130","doi-asserted-by":"crossref","first-page":"1465","DOI":"10.1097\/00001756-199606170-00004","article-title":"An ICE inhibitor, z-VAD-DCB attenuates ischaemic brain damage in the rat","volume":"7","author":"Loddick","year":"1996","journal-title":"Neuroreport"},{"key":"ref_131","doi-asserted-by":"crossref","first-page":"4398","DOI":"10.1523\/JNEUROSCI.20-12-04398.2000","article-title":"Inhibition of caspase-1-like activity by Ac-Tyr-Val-Ala-Asp-chloromethyl ketone induces long-lasting neuroprotection in cerebral ischemia through apoptosis reduction and decrease of proinflammatory cytokines","volume":"20","author":"Rabuffetti","year":"2000","journal-title":"J. Neurosci."},{"key":"ref_132","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1038\/417074a","article-title":"Minocycline inhibits cytochrome c release and delays progression of amyotrophic lateral sclerosis in mice","volume":"417","author":"Zhu","year":"2002","journal-title":"Nature"},{"key":"ref_133","doi-asserted-by":"crossref","first-page":"15318","DOI":"10.1073\/pnas.261323298","article-title":"BID mediates neuronal cell death after oxygen\/glucose deprivation and focal cerebral ischemia","volume":"98","author":"Plesnila","year":"2001","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_134","doi-asserted-by":"crossref","first-page":"1365","DOI":"10.1056\/NEJMra022366","article-title":"Apoptosis and caspases in neurodegenerative diseases","volume":"348","author":"Friedlander","year":"2003","journal-title":"N. Engl. J. Med."},{"key":"ref_135","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1126\/science.288.5464.335","article-title":"Functional role of caspase-1 and caspase-3 in an ALS transgenic mouse model","volume":"288","author":"Li","year":"2000","journal-title":"Science"},{"key":"ref_136","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1517\/14728222.2012.661416","article-title":"COX inhibitors for airway inflammation","volume":"16","author":"Malhotra","year":"2012","journal-title":"Expert Opin. Ther. Targets"},{"key":"ref_137","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1186\/s12935-015-0260-7","article-title":"Cyclooxygenase-2 promotes tumor growth and suppresses tumor immunity","volume":"15","author":"Liu","year":"2015","journal-title":"Cancer Cell Int."},{"key":"ref_138","doi-asserted-by":"crossref","first-page":"371","DOI":"10.1016\/0896-6273(93)90192-T","article-title":"Expression of a mitogen-inducible cyclooxygenase in brain neurons: Regulation by synaptic activity and glucocorticoids","volume":"11","author":"Yamagata","year":"1993","journal-title":"Neuron"},{"key":"ref_139","doi-asserted-by":"crossref","first-page":"296","DOI":"10.1002\/cne.903550208","article-title":"Characterization of inducible cyclooxygenase in rat brain","volume":"355","author":"Breder","year":"1995","journal-title":"J. Comp. Neurol."},{"key":"ref_140","doi-asserted-by":"crossref","first-page":"33157","DOI":"10.1074\/jbc.271.52.33157","article-title":"Prostaglandin endoperoxide H synthases (cyclooxygenases)-1 and\u2212 2","volume":"271","author":"Smith","year":"1996","journal-title":"J. Biol. Chem."},{"key":"ref_141","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1016\/0014-5793(93)80263-T","article-title":"Expression of mRNA for cyclooxygenase-1 and cyclooxygenase-2 in human tissues","volume":"330","year":"1993","journal-title":"FEBS Lett."},{"key":"ref_142","doi-asserted-by":"crossref","first-page":"226","DOI":"10.1016\/S0006-8993(99)01389-X","article-title":"Distribution of cyclooxygenase-1 and cyclooxygenase-2 mRNAs and proteins in human brain and peripheral organs","volume":"830","author":"Yasojima","year":"1999","journal-title":"Brain Res."},{"key":"ref_143","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1007\/s004010000251","article-title":"Cyclooxygenase expression in microglia and neurons in Alzheimer\u2019s disease and control brain","volume":"101","author":"Hoozemans","year":"2001","journal-title":"Acta Neuropathol."},{"key":"ref_144","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1016\/S0306-4522(98)00218-8","article-title":"Cyclooxygenase-2 expression is increased in frontal cortex of Alzheimer\u2019s disease brain","volume":"87","author":"Pasinetti","year":"1998","journal-title":"Neuroscience"},{"key":"ref_145","doi-asserted-by":"crossref","first-page":"423","DOI":"10.1159\/000101957","article-title":"Altered expression of COX-2 in subdivisions of the hippocampus during aging and in Alzheimer\u2019s disease: The Hisayama Study","volume":"23","author":"Fujimi","year":"2007","journal-title":"Dement. Geriatr. Cogn. Disord."},{"key":"ref_146","doi-asserted-by":"crossref","first-page":"823","DOI":"10.1016\/S0197-4580(01)00303-7","article-title":"Downregulation of neuronal cyclooxygenase-2 expression in end stage Alzheimer\u2019s disease","volume":"22","author":"Yermakova","year":"2001","journal-title":"Neurobiol. Aging"},{"key":"ref_147","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1136\/jnnp.2005.063131","article-title":"Levels of CSF prostaglandin E2, cognitive decline, and survival in Alzheimer\u2019s disease","volume":"77","author":"Combrinck","year":"2006","journal-title":"J. Neurol. Neurosurg. Psychiatry"},{"key":"ref_148","doi-asserted-by":"crossref","first-page":"1495","DOI":"10.1212\/WNL.53.7.1495","article-title":"Elevated CSF prostaglandin E2 levels in patients with probable AD","volume":"53","author":"Montine","year":"1999","journal-title":"Neurology"},{"key":"ref_149","doi-asserted-by":"crossref","first-page":"1419","DOI":"10.2174\/138161208784480171","article-title":"Cyclooxygenase-1 and-2 in the different stages of Alzheimer\u2019s disease pathology","volume":"14","author":"Hoozemans","year":"2008","journal-title":"Curr. Pharm. Des."},{"key":"ref_150","doi-asserted-by":"crossref","first-page":"14850","DOI":"10.1523\/JNEUROSCI.3922-11.2011","article-title":"Ablation of cyclooxygenase-2 in forebrain neurons is neuroprotective and dampens brain inflammation after status epilepticus","volume":"31","author":"Serrano","year":"2011","journal-title":"J. Neurosci."},{"key":"ref_151","doi-asserted-by":"crossref","first-page":"5473","DOI":"10.1073\/pnas.0837397100","article-title":"Cyclooxygenase-2 is instrumental in Parkinson\u2019s disease neurodegeneration","volume":"100","author":"Teismann","year":"2003","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_152","first-page":"534","article-title":"Navigating neurological disorders: Harnessing the power of natural compounds for innovative therapeutic breakthroughs","volume":"23","author":"Rushendran","year":"2024","journal-title":"EXCLI J."},{"key":"ref_153","doi-asserted-by":"crossref","first-page":"2411","DOI":"10.1021\/acs.jafc.3c07536","article-title":"Therapeutic potential of natural compounds from herbs and nutraceuticals in alleviating neurological disorders: Targeting the Wnt signaling pathway","volume":"72","author":"Li","year":"2024","journal-title":"J. Agric. Food Chem."},{"key":"ref_154","doi-asserted-by":"crossref","unstructured":"Yousaf, M., Chang, D., Liu, Y., Liu, T., and Zhou, X. (2022). Neuroprotection of cannabidiol, its synthetic derivatives and combination preparations against microglia-mediated neuroinflammation in neurological disorders. Molecules, 27.","DOI":"10.3390\/molecules27154961"},{"key":"ref_155","doi-asserted-by":"crossref","unstructured":"Puri, V., Kanojia, N., Sharma, A., Huanbutta, K., Dheer, D., and Sangnim, T. (2022). Natural product-based pharmacological studies for neurological disorders. Front. Pharmacol., 13.","DOI":"10.3389\/fphar.2022.1011740"},{"key":"ref_156","doi-asserted-by":"crossref","unstructured":"Rauf, A., and Rahman, M.M. (2022). Potential therapeutics against neurological disorders: Natural products-based drugs. Front. Pharmacol., 13.","DOI":"10.3389\/fphar.2022.950457"},{"key":"ref_157","doi-asserted-by":"crossref","first-page":"1943","DOI":"10.2174\/1568026616666160204122449","article-title":"Neuroprotective role of natural polyphenols","volume":"16","author":"Spagnuolo","year":"2016","journal-title":"Curr. Top. Med. Chem."},{"key":"ref_158","doi-asserted-by":"crossref","unstructured":"Ribaudo, G., Memo, M., and Gianoncelli, A. (2021). Multi-target natural and nature-inspired compounds against neurodegeneration: A focus on dual cholinesterase and phosphodiesterase inhibitors. Appl. Sci., 11.","DOI":"10.3390\/app11115044"},{"key":"ref_159","doi-asserted-by":"crossref","first-page":"105013","DOI":"10.1016\/j.neuint.2021.105013","article-title":"Neuro-nutraceutical potential of Asparagus racemosus: A review","volume":"145","author":"Majumdar","year":"2021","journal-title":"Neurochem. Int."},{"key":"ref_160","doi-asserted-by":"crossref","unstructured":"Bertelli, A., Biagi, M., Corsini, M., Baini, G., Cappellucci, G., and Miraldi, E. (2021). Polyphenols: From theory to practice. Foods, 10.","DOI":"10.3390\/foods10112595"},{"key":"ref_161","doi-asserted-by":"crossref","unstructured":"Froldi, G., and Ragazzi, E. (2022). Selected plant-derived polyphenols as potential therapeutic agents for peripheral artery disease: Molecular mechanisms, efficacy and safety. Molecules, 27.","DOI":"10.3390\/molecules27207110"},{"key":"ref_162","doi-asserted-by":"crossref","unstructured":"Breuss, J.M., Atanasov, A.G., and Uhrin, P. (2019). Resveratrol and its effects on the vascular system. Int. J. Mol. Sci., 20.","DOI":"10.3390\/ijms20071523"},{"key":"ref_163","doi-asserted-by":"crossref","first-page":"1851","DOI":"10.1002\/med.21565","article-title":"Health benefits of resveratrol: Evidence from clinical studies","volume":"39","author":"Singh","year":"2019","journal-title":"Med. Res. Rev."},{"key":"ref_164","doi-asserted-by":"crossref","first-page":"4713","DOI":"10.2147\/DDDT.S327238","article-title":"Therapeutic effects and safe uses of plant-derived polyphenolic compounds in cardiovascular diseases: A review","volume":"15","author":"Alotaibi","year":"2021","journal-title":"Drug Des. Dev. Ther."},{"key":"ref_165","doi-asserted-by":"crossref","unstructured":"Iqbal, I., Wilairatana, P., Saqib, F., Nasir, B., Wahid, M., Latif, M.F., Iqbal, A., Naz, R., and Mubarak, M.S. (2023). Plant polyphenols and their potential benefits on cardiovascular health: A review. Molecules, 28.","DOI":"10.3390\/molecules28176403"},{"key":"ref_166","doi-asserted-by":"crossref","first-page":"2040","DOI":"10.1080\/10408398.2018.1437023","article-title":"Polyphenols and bioavailability: An update","volume":"59","author":"Teng","year":"2019","journal-title":"Crit. Rev. Food Sci. Nutr."},{"key":"ref_167","doi-asserted-by":"crossref","unstructured":"Yang, B., Dong, Y., Wang, F., and Zhang, Y. (2020). Nanoformulations to enhance the bioavailability and physiological functions of polyphenols. Molecules, 25.","DOI":"10.3390\/molecules25204613"},{"key":"ref_168","doi-asserted-by":"crossref","first-page":"5177","DOI":"10.3390\/nu7075177","article-title":"A systematic review of the efficacy of bioactive compounds in cardiovascular disease: Phenolic compounds","volume":"7","author":"Aguilera","year":"2015","journal-title":"Nutrients"},{"key":"ref_169","doi-asserted-by":"crossref","first-page":"1235","DOI":"10.1166\/asem.2014.1630","article-title":"Introduction and interpretation of flavonoids","volume":"6","author":"Muhaisen","year":"2014","journal-title":"Adv. Sci. Eng. Med."},{"key":"ref_170","doi-asserted-by":"crossref","unstructured":"Khajuria, R., Singh, S., and Bahl, A. (2019). General introduction and sources of flavonoids. Current Aspects of Flavonoids: Their Role in Cancer Treatment, Springer.","DOI":"10.1007\/978-981-13-5874-6_1"},{"key":"ref_171","doi-asserted-by":"crossref","first-page":"474","DOI":"10.1016\/j.bioorg.2019.03.034","article-title":"Semi-synthetic isoflavones as BACE-1 inhibitors against Alzheimer\u2019s disease","volume":"87","author":"Ribaudo","year":"2019","journal-title":"Bioorg. Chem."},{"key":"ref_172","doi-asserted-by":"crossref","first-page":"206","DOI":"10.1016\/j.ejmech.2014.07.013","article-title":"Flavones: An important scaffold for medicinal chemistry","volume":"84","author":"Singh","year":"2014","journal-title":"Eur. J. Med. Chem."},{"key":"ref_173","doi-asserted-by":"crossref","first-page":"138","DOI":"10.1002\/jnr.20610","article-title":"Neuroprotective mechanisms of curcumin against cerebral ischemia-induced neuronal apoptosis and behavioral deficits","volume":"82","author":"Wang","year":"2005","journal-title":"J. Neurosci. Res."},{"key":"ref_174","doi-asserted-by":"crossref","first-page":"2105","DOI":"10.1007\/s11064-004-6883-z","article-title":"Resveratrol protects against neurotoxicity induced by kainic acid","volume":"29","author":"Wang","year":"2004","journal-title":"Neurochem. Res."},{"key":"ref_175","doi-asserted-by":"crossref","unstructured":"Simeonova, R., Zheleva, D., Valkova, I., Stavrakov, G., Philipova, I., Atanasova, M., and Doytchinova, I. (2021). A novel galantamine-curcumin hybrid as a potential multi-target agent against neurodegenerative disorders. Molecules, 26.","DOI":"10.3390\/molecules26071865"},{"key":"ref_176","doi-asserted-by":"crossref","first-page":"878","DOI":"10.1016\/j.neuint.2007.10.005","article-title":"Apigenin inhibits the production of NO and PGE2 in microglia and inhibits neuronal cell death in a middle cerebral artery occlusion-induced focal ischemia mice model","volume":"52","author":"Ha","year":"2008","journal-title":"Neurochem. Int."},{"key":"ref_177","doi-asserted-by":"crossref","unstructured":"Madeswaran, A., and Mohan, S. (2023). Neuroprotective effects of terpenoids against streptozotocin-nicotinamide-induced diabetic rats: An in silico, in vitro and in vivo study. Int. J. Biol. Macromol., 247.","DOI":"10.1016\/j.ijbiomac.2023.125817"},{"key":"ref_178","doi-asserted-by":"crossref","first-page":"51","DOI":"10.2174\/138161212798919101","article-title":"Neuroprotective effects of lutein in the retina","volume":"18","author":"Ozawa","year":"2012","journal-title":"Curr. Pharm. Des."},{"key":"ref_179","doi-asserted-by":"crossref","first-page":"104693","DOI":"10.1016\/j.arabjc.2023.104693","article-title":"Assessing neuroprotective efficacy of phytochemical saponin ruscogenin in both in vitro and in vivo model","volume":"16","author":"Wu","year":"2023","journal-title":"Arab. J. Chem."},{"key":"ref_180","doi-asserted-by":"crossref","first-page":"404","DOI":"10.1111\/j.1745-4514.2009.00228.x","article-title":"Anti-oxidant effect of quercetin on type 2 diabetic erythrocytes","volume":"33","author":"Rizvi","year":"2009","journal-title":"J. Food Biochem."},{"key":"ref_181","doi-asserted-by":"crossref","first-page":"186","DOI":"10.1007\/s00044-009-9183-y","article-title":"Protection of protein carbonyl formation by quercetin in erythrocytes subjected to oxidative stress","volume":"19","author":"Pandey","year":"2010","journal-title":"Med. Chem. Res."},{"key":"ref_182","doi-asserted-by":"crossref","first-page":"189","DOI":"10.2174\/1876396001104010189","article-title":"Beneficial effects of quercetin on obesity and diabetes","volume":"4","author":"Aguirre","year":"2011","journal-title":"Open Nutraceuticals J."},{"key":"ref_183","doi-asserted-by":"crossref","first-page":"140","DOI":"10.1016\/j.neuint.2015.07.002","article-title":"Quercetin in brain diseases: Potential and limits","volume":"89","author":"Dajas","year":"2015","journal-title":"Neurochem. Int."},{"key":"ref_184","doi-asserted-by":"crossref","first-page":"907","DOI":"10.1038\/nnano.2014.208","article-title":"Self-assembled micellar nanocomplexes comprising green tea catechin derivatives and protein drugs for cancer therapy","volume":"9","author":"Chung","year":"2014","journal-title":"Nat. Nanotechnol."},{"key":"ref_185","doi-asserted-by":"crossref","first-page":"297","DOI":"10.3892\/or.2014.3555","article-title":"Molecular mechanism of epigallocatechin-3-gallate in human esophageal squamous cell carcinoma in vitro and in vivo","volume":"33","author":"Liu","year":"2015","journal-title":"Oncol. Rep."},{"key":"ref_186","doi-asserted-by":"crossref","first-page":"1344","DOI":"10.1016\/j.phymed.2016.07.005","article-title":"Anti-cancer effect of (-)-epigallocatechin-3-gallate (EGCG) in head and neck cancer through repression of transactivation and enhanced degradation of \u03b2-catenin","volume":"23","author":"Shin","year":"2016","journal-title":"Phytomedicine"},{"key":"ref_187","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/s12032-014-0390-0","article-title":"(\u2212)-Epigallocatechin-3-gallate induces cancer cell apoptosis via acetylation of amyloid precursor protein","volume":"32","author":"Hu","year":"2015","journal-title":"Med. Oncol."},{"key":"ref_188","doi-asserted-by":"crossref","first-page":"1033","DOI":"10.1016\/j.bbrc.2009.01.007","article-title":"(\u2212)-Epigallocatechin gallate inhibition of osteoclastic differentiation via NF-\u03baB","volume":"379","author":"Lin","year":"2009","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"ref_189","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1254\/jphs.11082FP","article-title":"Tea polyphenols inhibit rat osteoclast formation and differentiation","volume":"118","author":"Oka","year":"2012","journal-title":"J. Pharmacol. Sci."},{"key":"ref_190","doi-asserted-by":"crossref","first-page":"684","DOI":"10.1016\/j.bone.2008.11.018","article-title":"Green tea polyphenols mitigate deterioration of bone microarchitecture in middle-aged female rats","volume":"44","author":"Shen","year":"2009","journal-title":"Bone"},{"key":"ref_191","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1016\/0304-3835(93)90026-6","article-title":"Enhancement of gap junctional intercellular communication in tumor promoter-treated cells by components of green tea","volume":"69","author":"Sigler","year":"1993","journal-title":"Cancer Lett."},{"key":"ref_192","doi-asserted-by":"crossref","first-page":"1698S","DOI":"10.1093\/ajcn\/71.6.1698S","article-title":"Tea polyphenols: Prevention of cancer and optimizing health","volume":"71","author":"Mukhtar","year":"2000","journal-title":"Am. J. Clin. Nutr."},{"key":"ref_193","doi-asserted-by":"crossref","first-page":"206","DOI":"10.1249\/JSR.0b013e3181ae8959","article-title":"Effects of the dietary flavonoid quercetin upon performance and health","volume":"8","author":"Davis","year":"2009","journal-title":"Curr. Sports Med. Rep."},{"key":"ref_194","first-page":"138","article-title":"Quercetin and its derivatives: Synthesis, pharmacological uses with special emphasis on anti-tumor properties and prodrug with enhanced bio-availability","volume":"9","author":"Hirpara","year":"2009","journal-title":"Anti-Cancer Agents Med. Chem. (Former. Curr. Med. Chem.-Anti-Cancer Agents)"},{"key":"ref_195","doi-asserted-by":"crossref","first-page":"1451","DOI":"10.2174\/092986709787909578","article-title":"Chemoprotective mechanism of the natural compounds, epigallocatechin-3-O-gallate, quercetin and curcumin against cancer and cardiovascular diseases","volume":"16","author":"Jagtap","year":"2009","journal-title":"Curr. Med. Chem."},{"key":"ref_196","doi-asserted-by":"crossref","first-page":"493","DOI":"10.1177\/0960327109107002","article-title":"Quercetin-induced apoptosis acts through mitochondrial-and caspase-3-dependent pathways in human breast cancer MDA-MB-231 cells","volume":"28","author":"Chien","year":"2009","journal-title":"Hum. Exp. Toxicol."},{"key":"ref_197","doi-asserted-by":"crossref","first-page":"2715","DOI":"10.1093\/jn\/136.11.2715","article-title":"Quercetin induces apoptosis via caspase activation, regulation of Bcl-2, and inhibition of PI-3-kinase\/Akt and ERK pathways in a human hepatoma cell line (HepG2)","volume":"136","author":"Bravo","year":"2006","journal-title":"J. Nutr."},{"key":"ref_198","doi-asserted-by":"crossref","first-page":"797","DOI":"10.1016\/j.tiv.2009.04.007","article-title":"Cytotoxicity of flavones and flavonols to a human esophageal squamous cell carcinoma cell line (KYSE-510) by induction of G2\/M arrest and apoptosis","volume":"23","author":"Zhang","year":"2009","journal-title":"Toxicol. Vitr."},{"key":"ref_199","doi-asserted-by":"crossref","first-page":"810","DOI":"10.2741\/e142","article-title":"EGCG and quercetin protected INS-1 cells in oxidative stress via different mechanisms","volume":"2","author":"Kim","year":"2010","journal-title":"Front. Biosci. (Elite Ed.)"},{"key":"ref_200","doi-asserted-by":"crossref","first-page":"850","DOI":"10.1007\/s10495-010-0497-5","article-title":"Activation of PI3K\/Akt\/IKK-\u03b1\/NF-\u03baB signaling pathway is required for the apoptosis-evasion in human salivary adenoid cystic carcinoma: Its inhibition by quercetin","volume":"15","author":"Sun","year":"2010","journal-title":"Apoptosis"},{"key":"ref_201","doi-asserted-by":"crossref","first-page":"590","DOI":"10.1097\/WNR.0000000000000803","article-title":"(\u2212)-Epigallocatechin-3-gallate ameliorates memory impairment and rescues the abnormal synaptic protein levels in the frontal cortex and hippocampus in a mouse model of Alzheimer\u2019s disease","volume":"28","author":"Guo","year":"2017","journal-title":"Neuroreport"},{"key":"ref_202","doi-asserted-by":"crossref","first-page":"136","DOI":"10.1016\/j.yexcr.2015.04.004","article-title":"(\u2212)-Epigallocatechin-3-gallate attenuates cognitive deterioration in Alzheimer\u2019s disease model mice by upregulating neprilysin expression","volume":"334","author":"Chang","year":"2015","journal-title":"Exp. Cell Res."},{"key":"ref_203","doi-asserted-by":"crossref","first-page":"2417S","DOI":"10.1093\/jn\/133.7.2417S","article-title":"Molecular targets for green tea in prostate cancer prevention","volume":"133","author":"Adhami","year":"2003","journal-title":"J. Nutr."},{"key":"ref_204","doi-asserted-by":"crossref","first-page":"1006","DOI":"10.1158\/1535-7163.MCT-06-0491","article-title":"Protein kinase CK2 modulates apoptosis induced by resveratrol and epigallocatechin-3-gallate in prostate cancer cells","volume":"6","author":"Ahmad","year":"2007","journal-title":"Mol. Cancer Ther."},{"key":"ref_205","doi-asserted-by":"crossref","first-page":"338","DOI":"10.1006\/abbi.2000.1742","article-title":"Green tea polyphenol epigallocatechin-3-gallate differentially modulates nuclear factor \u03baB in cancer cells versus normal cells","volume":"376","author":"Ahmad","year":"2000","journal-title":"Arch. Biochem. Biophys."},{"key":"ref_206","doi-asserted-by":"crossref","first-page":"141","DOI":"10.26650\/IstanbulJPharm.2020.0056","article-title":"Bioavailability of berberine: Challenges and solutions","volume":"51","author":"Thomas","year":"2021","journal-title":"\u0130stanbul J. Pharm."},{"key":"ref_207","doi-asserted-by":"crossref","unstructured":"Behl, T., Singh, S., Sharma, N., Zahoor, I., Albarrati, A., Albratty, M., Meraya, A.M., Najmi, A., and Bungau, S. (2022). Expatiating the pharmacological and nanotechnological aspects of the alkaloidal drug berberine: Current and future trends. Molecules, 27.","DOI":"10.3390\/molecules27123705"},{"key":"ref_208","doi-asserted-by":"crossref","first-page":"288","DOI":"10.1016\/j.ejphar.2015.05.068","article-title":"Current knowledge and pharmacological profile of berberine: An update","volume":"761","author":"Kumar","year":"2015","journal-title":"Eur. J. Pharmacol."},{"key":"ref_209","doi-asserted-by":"crossref","first-page":"E955","DOI":"10.1152\/ajpendo.90599.2008","article-title":"Berberine suppresses proinflammatory responses through AMPK activation in macrophages","volume":"296","author":"Jeong","year":"2009","journal-title":"Am. J. Physiol.-Endocrinol. Metab."},{"key":"ref_210","doi-asserted-by":"crossref","first-page":"217019","DOI":"10.1016\/j.canlet.2024.217019","article-title":"Unlocking the Potential of Berberine: Advancing Cancer Therapy through Chemosensitization and Combination Treatments","volume":"597","author":"Sajeev","year":"2024","journal-title":"Cancer Lett."},{"key":"ref_211","doi-asserted-by":"crossref","first-page":"705","DOI":"10.1208\/s12249-011-9632-z","article-title":"Bioavailability study of berberine and the enhancing effects of TPGS on intestinal absorption in rats","volume":"12","author":"Chen","year":"2011","journal-title":"Aaps Pharmscitech"},{"key":"ref_212","doi-asserted-by":"crossref","first-page":"1779","DOI":"10.1124\/dmd.110.033936","article-title":"Extensive intestinal first-pass elimination and predominant hepatic distribution of berberine explain its low plasma levels in rats","volume":"38","author":"Liu","year":"2010","journal-title":"Drug Metab. Dispos."},{"key":"ref_213","doi-asserted-by":"crossref","first-page":"1419","DOI":"10.1080\/17460913.2024.2398337","article-title":"Application of microbial enzymes in medicine and industry: Current status and future perspectives","volume":"19","author":"Darbandi","year":"2024","journal-title":"Future Microbiol."},{"key":"ref_214","unstructured":"West, S. (1996). Industrial Enzymology, Stockton Press."},{"key":"ref_215","doi-asserted-by":"crossref","first-page":"597","DOI":"10.1128\/MMBR.62.3.597-635.1998","article-title":"Molecular and biotechnological aspects of microbial proteases","volume":"62","author":"Rao","year":"1998","journal-title":"Microbiol. Mol. Biol. Rev."},{"key":"ref_216","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1042\/bj2900205","article-title":"Evolutionary families of peptidases","volume":"290","author":"Rawlings","year":"1993","journal-title":"Biochem. J."},{"key":"ref_217","doi-asserted-by":"crossref","first-page":"83","DOI":"10.4103\/0975-7406.171700","article-title":"Exploring the ocean for new drug developments: Marine pharmacology","volume":"8","author":"Malve","year":"2016","journal-title":"J. Pharm. Bioallied Sci."},{"key":"ref_218","doi-asserted-by":"crossref","first-page":"3755","DOI":"10.1007\/s00253-015-6518-0","article-title":"Marine lectins and their medicinal applications","volume":"99","author":"Cheung","year":"2015","journal-title":"Appl. Microbiol. Biotechnol."},{"key":"ref_219","doi-asserted-by":"crossref","first-page":"334","DOI":"10.2174\/1389203719666180926121722","article-title":"The place for enzymes and biologically active peptides from marine organisms for application in industrial and pharmaceutical biotechnology","volume":"20","author":"Morlighem","year":"2019","journal-title":"Curr. Protein Pept. Sci."},{"key":"ref_220","doi-asserted-by":"crossref","unstructured":"Bakunina, I., Likhatskaya, G., Slepchenko, L., Balabanova, L., Tekutyeva, L., Son, O., Shubina, L., and Makarieva, T. (2019). Effect of pentacyclic guanidine alkaloids from the sponge Monanchora pulchra on activity of \u03b1-glycosidases from marine bacteria. Mar. Drugs, 17.","DOI":"10.3390\/md17010022"},{"key":"ref_221","doi-asserted-by":"crossref","first-page":"7969","DOI":"10.1016\/S0040-4039(00)78398-5","article-title":"Arenastatin A, a potent cytotoxic depsipeptide from the Okinawan marine sponge Dysidea arenaria","volume":"35","author":"Kobayashi","year":"1994","journal-title":"Tetrahedron Lett."},{"key":"ref_222","doi-asserted-by":"crossref","first-page":"766","DOI":"10.1021\/cb6004307","article-title":"Biosynthetic characterization and chemoenzymatic assembly of the cryptophycins. Potent anticancer agents from Nostoc cyanobionts","volume":"1","author":"Magarvey","year":"2006","journal-title":"ACS Chem. Biol."},{"key":"ref_223","unstructured":"Boyer, P.D., and Krebs, E.G. (1986). The enzymes, Academic Press."},{"key":"ref_224","first-page":"146","article-title":"Food related enzymes","volume":"136","author":"Hoffman","year":"1974","journal-title":"Adv. Chem. Ser."},{"key":"ref_225","doi-asserted-by":"crossref","first-page":"126","DOI":"10.1186\/s43094-024-00709-y","article-title":"Trypsin, chymotrypsin and elastase in health and disease","volume":"10","author":"Famutimi","year":"2024","journal-title":"Future J. Pharm. Sci."},{"key":"ref_226","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1007\/s12325-017-0648-y","article-title":"The role of trypsin: Chymotrypsin in tissue repair","volume":"35","author":"Shah","year":"2018","journal-title":"Adv. Ther."},{"key":"ref_227","doi-asserted-by":"crossref","unstructured":"Iqbal, D., Rizvi, S.M.D., Rehman, M.T., Khan, M.S., Bin Dukhyil, A., AlAjmi, M.F., Alshehri, B.M., Banawas, S., Zia, Q., and Alsaweed, M. (2022). Soyasapogenol-B as a potential multitarget therapeutic agent for neurodegenerative disorders: Molecular docking and dynamics study. Entropy, 24.","DOI":"10.3390\/e24050593"},{"key":"ref_228","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1016\/j.colsurfb.2019.01.027","article-title":"Erythropoietin-loaded solid lipid nanoparticles: Preparation, optimization, and in vivo evaluation","volume":"178","author":"Dara","year":"2019","journal-title":"Colloids Surf. B Biointerfaces"},{"key":"ref_229","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1016\/j.ejps.2015.07.002","article-title":"Application of quality by design approach for intranasal delivery of rivastigmine loaded solid lipid nanoparticles: Effect on formulation and characterization parameters","volume":"78","author":"Shah","year":"2015","journal-title":"Eur. J. Pharm. Sci."},{"key":"ref_230","doi-asserted-by":"crossref","first-page":"16962","DOI":"10.1039\/C8NR04073G","article-title":"Treatment of neurodegenerative disorders through the blood\u2013brain barrier using nanocarriers","volume":"10","author":"Poovaiah","year":"2018","journal-title":"Nanoscale"},{"key":"ref_231","doi-asserted-by":"crossref","first-page":"192","DOI":"10.1016\/j.ijpharm.2013.11.049","article-title":"Intranasal nanoparticles of basic fibroblast growth factor for brain delivery to treat Alzheimer\u2019s disease","volume":"461","author":"Zhang","year":"2014","journal-title":"Int. J. Pharm."},{"key":"ref_232","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1016\/j.bbr.2009.06.012","article-title":"Scopolamine-induced deficits in social memory in mice: Reversal by donepezil","volume":"204","author":"Riedel","year":"2009","journal-title":"Behav. Brain Res."},{"key":"ref_233","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1007\/s002130050592","article-title":"Chronic haloperidol produces a time-and dose-related slowing of lick rhythm in rats: Implications for rodent models of tardive dyskinesia and neuroleptic-induced parkinsonism","volume":"137","author":"Fowler","year":"1998","journal-title":"Psychopharmacology"},{"key":"ref_234","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1016\/S0014-2999(98)00393-8","article-title":"Effect of trihexyphenidyl, a non-selective antimuscarinic drug, on decarboxylation of L-dopa in hemi-Parkinson rats","volume":"353","author":"Sarre","year":"1998","journal-title":"Eur. J. Pharmacol."},{"key":"ref_235","doi-asserted-by":"crossref","first-page":"109684","DOI":"10.1016\/j.neuropharm.2023.109684","article-title":"(R, S)-trihexyphenidyl, acting via a muscarinic receptor-independent mechanism, inhibits hippocampal glutamatergic and GABAergic synaptic transmissions: Potential relevance for treatment of organophosphorus intoxication","volume":"239","author":"Aracava","year":"2023","journal-title":"Neuropharmacology"},{"key":"ref_236","doi-asserted-by":"crossref","first-page":"1199","DOI":"10.1523\/JNEUROSCI.4129-14.2015","article-title":"The potent BACE1 inhibitor LY2886721 elicits robust central A\u03b2 pharmacodynamic responses in mice, dogs, and humans","volume":"35","author":"May","year":"2015","journal-title":"J. Neurosci."},{"key":"ref_237","doi-asserted-by":"crossref","first-page":"1078","DOI":"10.1016\/S0140-6736(20)30164-1","article-title":"Small molecules, big impact: 20 years of targeted therapy in oncology","volume":"395","author":"Bedard","year":"2020","journal-title":"Lancet"},{"key":"ref_238","doi-asserted-by":"crossref","first-page":"e181","DOI":"10.1002\/mco2.181","article-title":"Small molecule inhibitors targeting the cancers","volume":"3","author":"Liu","year":"2022","journal-title":"MedComm"},{"key":"ref_239","doi-asserted-by":"crossref","first-page":"551","DOI":"10.1038\/s41573-021-00195-4","article-title":"Kinase drug discovery 20 years after imatinib: Progress and future directions","volume":"20","author":"Cohen","year":"2021","journal-title":"Nat. Rev. Drug Discov."},{"key":"ref_240","doi-asserted-by":"crossref","first-page":"839","DOI":"10.1038\/s41573-021-00252-y","article-title":"Trends in kinase drug discovery: Targets, indications and inhibitor design","volume":"20","author":"Attwood","year":"2021","journal-title":"Nat. Rev. Drug Discov."},{"key":"ref_241","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1038\/nrd.2018.21","article-title":"Kinase inhibitors: The road ahead","volume":"17","author":"Ferguson","year":"2018","journal-title":"Nat. Rev. Drug Discov."},{"key":"ref_242","doi-asserted-by":"crossref","first-page":"404","DOI":"10.1038\/s41556-022-00892-1","article-title":"Membranes regulate biomolecular condensates","volume":"24","author":"Case","year":"2022","journal-title":"Nat. Cell Biol."},{"key":"ref_243","doi-asserted-by":"crossref","first-page":"1260","DOI":"10.1200\/JCO.21.02310","article-title":"Efficacy, molecular biology, quality of life, or economic aspects: What do we really focus on?","volume":"40","author":"Kurreck","year":"2022","journal-title":"J. Clin. Oncol."},{"key":"ref_244","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1038\/s41571-018-0115-y","article-title":"Fibroblast growth factor receptors as treatment targets in clinical oncology","volume":"16","author":"Katoh","year":"2019","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"ref_245","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1158\/1078-0432.CCR-20-1600","article-title":"Flumatinib versus imatinib for newly diagnosed chronic phase chronic myeloid leukemia: A phase III, randomized, open-label, multi-center FESTnd study","volume":"27","author":"Zhang","year":"2021","journal-title":"Clin. Cancer Res."},{"key":"ref_246","doi-asserted-by":"crossref","first-page":"7180","DOI":"10.1158\/1078-0432.CCR-17-0957","article-title":"Phase III clinical trial (RERISE study) results of efficacy and safety of radotinib compared with imatinib in newly diagnosed chronic phase chronic myeloid leukemia","volume":"23","author":"Kwak","year":"2017","journal-title":"Clin. Cancer Res."},{"key":"ref_247","doi-asserted-by":"crossref","first-page":"611","DOI":"10.1200\/JCO.21.01626","article-title":"Targeted therapies for lung cancer patients with oncogenic driver molecular alterations","volume":"40","author":"Tan","year":"2022","journal-title":"J. Clin. Oncol."},{"key":"ref_248","doi-asserted-by":"crossref","first-page":"1268","DOI":"10.1158\/1078-0432.CCR-21-2037","article-title":"Phase II study of ponatinib in advanced gastrointestinal stromal tumors: Efficacy, safety, and impact of liquid biopsy and other biomarkers","volume":"28","author":"George","year":"2022","journal-title":"Clin. Cancer Res."},{"key":"ref_249","doi-asserted-by":"crossref","first-page":"550","DOI":"10.1016\/S1470-2045(15)70105-1","article-title":"Nilotinib versus imatinib as first-line therapy for patients with unresectable or metastatic gastrointestinal stromal tumours (ENESTg1): A randomised phase 3 trial","volume":"16","author":"Blay","year":"2015","journal-title":"Lancet Oncol."},{"key":"ref_250","doi-asserted-by":"crossref","first-page":"3182","DOI":"10.1200\/JCO.2012.47.7836","article-title":"Imatinib for melanomas harboring mutationally activated or amplified KIT arising on mucosal, acral, and chronically sun-damaged skin","volume":"31","author":"Hodi","year":"2013","journal-title":"J. Clin. Oncol."},{"key":"ref_251","doi-asserted-by":"crossref","first-page":"2904","DOI":"10.1200\/JCO.2010.33.9275","article-title":"Phase II, open-label, single-arm trial of imatinib mesylate in patients with metastatic melanoma harboring c-Kit mutation or amplification","volume":"29","author":"Guo","year":"2011","journal-title":"J. Clin. Oncol."},{"key":"ref_252","doi-asserted-by":"crossref","first-page":"2327","DOI":"10.1001\/jama.2011.746","article-title":"KIT as a therapeutic target in metastatic melanoma","volume":"305","author":"Carvajal","year":"2011","journal-title":"Jama"},{"key":"ref_253","doi-asserted-by":"crossref","first-page":"1344","DOI":"10.1016\/j.ejca.2010.02.014","article-title":"Phase II study of oral masitinib mesilate in imatinib-naive patients with locally advanced or metastatic gastro-intestinal stromal tumour (GIST)","volume":"46","author":"Blay","year":"2010","journal-title":"Eur. J. Cancer"},{"key":"ref_254","doi-asserted-by":"crossref","first-page":"8797","DOI":"10.1021\/acs.jmedchem.8b00938","article-title":"Discovery of N-(4-{[5-Fluoro-7-(2-methoxyethoxy) quinazolin-4-yl] amino} phenyl)-2-[4-(propan-2-yl)-1 H-1, 2, 3-triazol-1-yl] acetamide (AZD3229), a Potent Pan-KIT Mutant Inhibitor for the Treatment of Gastrointestinal Stromal Tumors","volume":"61","author":"Kettle","year":"2018","journal-title":"J. Med. Chem."},{"key":"ref_255","doi-asserted-by":"crossref","first-page":"3113","DOI":"10.2147\/DDDT.S468478","article-title":"Effect of Efavirenz on the Pharmacokinetics of SHR6390 in Healthy Volunteers","volume":"18","author":"Wang","year":"2024","journal-title":"Drug Des. Dev. Ther."},{"key":"ref_256","first-page":"742","article-title":"Tofacitinib-induced eosinophilia","volume":"115","author":"Archer","year":"2023","journal-title":"Rev. Esp. De Enfermadades Dig. (REED)"},{"key":"ref_257","doi-asserted-by":"crossref","first-page":"912","DOI":"10.21037\/atm-22-3582","article-title":"A lung adenocarcinoma patient with ROS1 fusion and NBN germline mutation achieves long progression-free survival from sintilimab combined with niraparib after failure of ROS1 inhibitors: A case report","volume":"10","author":"Xu","year":"2022","journal-title":"Ann. Transl. Med."},{"key":"ref_258","doi-asserted-by":"crossref","first-page":"175192","DOI":"10.1016\/j.ejphar.2022.175192","article-title":"In vivo degradation forms, anti-degradation strategies, and clinical applications of therapeutic peptides in non-infectious chronic diseases","volume":"932","author":"Tasdemiroglu","year":"2022","journal-title":"Eur. J. Pharmacol."},{"key":"ref_259","doi-asserted-by":"crossref","unstructured":"Yeo, X.Y., Cunliffe, G., Ho, R.C., Lee, S.S., and Jung, S. (2022). Potentials of neuropeptides as therapeutic agents for neurological diseases. Biomedicines, 10.","DOI":"10.3390\/biomedicines10020343"},{"key":"ref_260","doi-asserted-by":"crossref","first-page":"2583","DOI":"10.2174\/0929867321666140217124349","article-title":"A translational view of peptide treatment of neurological disorders","volume":"21","author":"Brinker","year":"2014","journal-title":"Curr. Med. Chem."},{"key":"ref_261","doi-asserted-by":"crossref","first-page":"3700","DOI":"10.1021\/acs.molpharmaceut.2c00523","article-title":"Peptides as pharmacological carriers to the brain: Promises, shortcomings and challenges","volume":"19","author":"Parrasia","year":"2022","journal-title":"Mol. Pharm."},{"key":"ref_262","doi-asserted-by":"crossref","first-page":"1081","DOI":"10.1021\/mp400680d","article-title":"Strategies to deliver peptide drugs to the brain","volume":"11","author":"Lalatsa","year":"2014","journal-title":"Mol. Pharm."},{"key":"ref_263","doi-asserted-by":"crossref","first-page":"715","DOI":"10.2174\/0929867324666171026163144","article-title":"Peptides and their metal complexes in neurodegenerative diseases: From structural studies to nanomedicine prospects","volume":"25","author":"Trapani","year":"2018","journal-title":"Curr. Med. Chem."},{"key":"ref_264","doi-asserted-by":"crossref","first-page":"2610","DOI":"10.2174\/0929867321666140217125857","article-title":"Peptide therapeutics in neurodegenerative disorders","volume":"21","author":"Tiwari","year":"2014","journal-title":"Curr. Med. Chem."},{"key":"ref_265","doi-asserted-by":"crossref","first-page":"559","DOI":"10.1016\/j.bcp.2011.10.014","article-title":"Peptide therapeutics for CNS indications","volume":"83","author":"McGonigle","year":"2012","journal-title":"Biochem. Pharmacol."},{"key":"ref_266","doi-asserted-by":"crossref","unstructured":"Paolino, D., Sinha, P., Fresta, M., and Ferrari, M. (2006). Drug delivery systems. Encycl. Med. Devices Instrum.","DOI":"10.1002\/0471732877.emd274"},{"key":"ref_267","doi-asserted-by":"crossref","first-page":"1712","DOI":"10.1158\/0008-5472.CAN-08-3978","article-title":"Introducing nanochemoprevention as a novel approach for cancer control: Proof of principle with green tea polyphenol epigallocatechin-3-gallate","volume":"69","author":"Siddiqui","year":"2009","journal-title":"Cancer Res."},{"key":"ref_268","doi-asserted-by":"crossref","first-page":"899","DOI":"10.1007\/s11095-006-9207-y","article-title":"Development of biodegradable nanoparticles for oral delivery of ellagic acid and evaluation of their antioxidant efficacy against cyclosporine A-induced nephrotoxicity in rats","volume":"24","author":"Sonaje","year":"2007","journal-title":"Pharm. Res."},{"key":"ref_269","doi-asserted-by":"crossref","first-page":"276","DOI":"10.1016\/j.jcis.2008.10.082","article-title":"(\u2212)-Epigallocatechin gallate\/gelatin layer-by-layer assembled films and microcapsules","volume":"330","author":"Shutava","year":"2009","journal-title":"J. Colloid Interface Sci."},{"key":"ref_270","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1080\/10611860400015977","article-title":"Physicochemical characteristics and in vivo deposition of liposome-encapsulated tea catechins by topical and intratumor administrations","volume":"13","author":"Fang","year":"2005","journal-title":"J. Drug Target."},{"key":"ref_271","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1002\/ijc.24336","article-title":"Liposome encapsulation of curcumin and resveratrol in combination reduces prostate cancer incidence in PTEN knockout mice","volume":"125","author":"Narayanan","year":"2009","journal-title":"Int. J. Cancer"},{"key":"ref_272","doi-asserted-by":"crossref","first-page":"1121","DOI":"10.1007\/s11095-011-0375-z","article-title":"Development and in vitro-in vivo evaluation of polymeric implants for continuous systemic delivery of curcumin","volume":"28","author":"Bansal","year":"2011","journal-title":"Pharm. Res."},{"key":"ref_273","doi-asserted-by":"crossref","first-page":"935","DOI":"10.1248\/bpb.24.935","article-title":"Molecular and pharmacokinetic properties of 222 commercially available oral drugs in humans","volume":"24","author":"Sakaeda","year":"2001","journal-title":"Biol. Pharm. Bull."},{"key":"ref_274","doi-asserted-by":"crossref","first-page":"1250","DOI":"10.1021\/jm021053p","article-title":"A comparison of physiochemical property profiles of development and marketed oral drugs","volume":"46","author":"Wenlock","year":"2003","journal-title":"J. Med. Chem."},{"key":"ref_275","doi-asserted-by":"crossref","first-page":"224","DOI":"10.1021\/jm030267j","article-title":"Characteristic physical properties and structural fragments of marketed oral drugs","volume":"47","author":"Vieth","year":"2004","journal-title":"J. Med. Chem."},{"key":"ref_276","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1517\/17425247.2.3.419","article-title":"Strategies to improve oral drug bioavailability","volume":"2","year":"2005","journal-title":"Expert Opin. Drug Deliv."},{"key":"ref_277","doi-asserted-by":"crossref","first-page":"2393","DOI":"10.1021\/jm0303812","article-title":"Lessons learned from marketed and investigational prodrugs","volume":"47","author":"Ettmayer","year":"2004","journal-title":"J. Med. Chem."},{"key":"ref_278","doi-asserted-by":"crossref","unstructured":"Zhuo, Y., Zhao, Y.-G., and Zhang, Y. (2024). Enhancing Drug Solubility, Bioavailability, and Targeted Therapeutic Applications through Magnetic Nanoparticles. Molecules, 29.","DOI":"10.3390\/molecules29204854"},{"key":"ref_279","doi-asserted-by":"crossref","first-page":"186","DOI":"10.1007\/s42452-024-05858-6","article-title":"PLA-HA\/Fe3O4 magnetic nanoparticles loaded with curcumin: Physicochemical characterization and toxicity evaluation in HCT116 colorectal cancer cells","volume":"6","author":"Bourang","year":"2024","journal-title":"Discov. Appl. Sci."},{"key":"ref_280","doi-asserted-by":"crossref","first-page":"1979","DOI":"10.2217\/nnm-2023-0261","article-title":"Recent advances in nanomaterials for neural applications: Opportunities and challenges","volume":"18","author":"Sisubalan","year":"2023","journal-title":"Nanomedicine"},{"key":"ref_281","doi-asserted-by":"crossref","unstructured":"Liu, C., Helsper, S., Marzano, M., Chen, X., Muok, L., Esmonde, C., Zeng, C., Sun, L., Grant, S.C., and Li, Y. (2022). Human forebrain organoid-derived extracellular vesicle labeling with iron oxides for in vitro magnetic resonance imaging. Biomedicines, 10.","DOI":"10.3390\/biomedicines10123060"},{"key":"ref_282","doi-asserted-by":"crossref","first-page":"740","DOI":"10.1208\/s12248-009-9144-x","article-title":"Prediction of solubility and permeability class membership: Provisional BCS classification of the world\u2019s top oral drugs","volume":"11","author":"Dahan","year":"2009","journal-title":"AAPS J."},{"key":"ref_283","doi-asserted-by":"crossref","first-page":"1499","DOI":"10.1016\/S0142-9612(00)00039-9","article-title":"Oral peptide drug delivery: Polymer\u2013inhibitor conjugates protecting insulin from enzymatic degradation in vitro","volume":"21","year":"2000","journal-title":"Biomaterials"},{"key":"ref_284","doi-asserted-by":"crossref","first-page":"337","DOI":"10.4155\/tde.14.5","article-title":"Recent developments in protein and peptide parenteral delivery approaches","volume":"5","author":"Patel","year":"2014","journal-title":"Ther. Deliv."},{"key":"ref_285","doi-asserted-by":"crossref","unstructured":"Raj, G.M., and Raveendran, R. (2019). Introduction to Basics of Pharmacology and Toxicology: Volume 1: General and Molecular Pharmacology: Principles of Drug Action, Springer Nature.","DOI":"10.1007\/978-981-32-9779-1"},{"key":"ref_286","first-page":"461","article-title":"Subcutaneous administration of biotherapeutics: Current experience in animal models","volume":"12","author":"McDonald","year":"2010","journal-title":"Curr. Opin. Mol. Ther."},{"key":"ref_287","doi-asserted-by":"crossref","first-page":"1261","DOI":"10.1038\/nbt.1504","article-title":"Transdermal drug delivery","volume":"26","author":"Prausnitz","year":"2008","journal-title":"Nat. Biotechnol."},{"key":"ref_288","doi-asserted-by":"crossref","first-page":"6520","DOI":"10.1039\/C6CS00409A","article-title":"Lipid-based nanovesicles for nanomedicine","volume":"45","author":"Grimaldi","year":"2016","journal-title":"Chem. Soc. Rev."},{"key":"ref_289","doi-asserted-by":"crossref","first-page":"758","DOI":"10.1007\/s13346-021-00909-6","article-title":"Enhancement strategies for transdermal drug delivery systems: Current trends and applications","volume":"12","author":"Ramadon","year":"2021","journal-title":"Drug Deliv. Transl. Res."},{"key":"ref_290","doi-asserted-by":"crossref","first-page":"1681","DOI":"10.1007\/s00044-024-03278-0","article-title":"Synthesis, in vitro activity, and molecular docking of caffeic acid and resveratrol derivatives against Alzheimer\u2019s disease-related enzymes","volume":"33","year":"2024","journal-title":"Med. Chem. Res."},{"key":"ref_291","doi-asserted-by":"crossref","unstructured":"Yetisgin, A.A., Cetinel, S., Zuvin, M., Kosar, A., and Kutlu, O. (2020). Therapeutic nanoparticles and their targeted delivery applications. Molecules, 25.","DOI":"10.3390\/molecules25092193"},{"key":"ref_292","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1080\/1061186X.2017.1377207","article-title":"Promising effects of nanomedicine in cancer drug delivery","volume":"26","author":"Wakaskar","year":"2018","journal-title":"J. Drug Target."},{"key":"ref_293","doi-asserted-by":"crossref","first-page":"941","DOI":"10.1038\/nbt.3330","article-title":"Principles of nanoparticle design for overcoming biological barriers to drug delivery","volume":"33","author":"Blanco","year":"2015","journal-title":"Nat. Biotechnol."},{"key":"ref_294","doi-asserted-by":"crossref","unstructured":"Afzal, O., Altamimi, A.S., Nadeem, M.S., Alzarea, S.I., Almalki, W.H., Tariq, A., Mubeen, B., Murtaza, B.N., Iftikhar, S., and Riaz, N. (2022). Nanoparticles in drug delivery: From history to therapeutic applications. Nanomaterials, 12.","DOI":"10.3390\/nano12244494"},{"key":"ref_295","doi-asserted-by":"crossref","first-page":"675","DOI":"10.1016\/j.ijpharm.2017.06.052","article-title":"Polymeric nanoparticles: Promising platform for drug delivery","volume":"528","author":"Khalid","year":"2017","journal-title":"Int. J. Pharm."},{"key":"ref_296","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1016\/j.ejps.2017.04.005","article-title":"Cancer nanotheranostics: A review of the role of conjugated ligands for overexpressed receptors","volume":"104","author":"Ramzy","year":"2017","journal-title":"Eur. J. Pharm. Sci."},{"key":"ref_297","doi-asserted-by":"crossref","unstructured":"Yao, Y., Zhou, Y., Liu, L., Xu, Y., Chen, Q., Wang, Y., Wu, S., Deng, Y., Zhang, J., and Shao, A. (2020). Nanoparticle-based drug delivery in cancer therapy and its role in overcoming drug resistance. Front. Mol. Biosci., 7.","DOI":"10.3389\/fmolb.2020.00193"},{"key":"ref_298","doi-asserted-by":"crossref","unstructured":"Waheed, S., Li, Z., Zhang, F., Chiarini, A., Armato, U., and Wu, J. (2022). Engineering nano-drug biointerface to overcome biological barriers toward precision drug delivery. J. Nanobiotechnol., 20.","DOI":"10.1186\/s12951-022-01605-4"},{"key":"ref_299","doi-asserted-by":"crossref","first-page":"2561","DOI":"10.1016\/j.biopha.2018.11.116","article-title":"Anti-inflammatory mechanism of various metal and metal oxide nanoparticles synthesized using plant extracts: A review","volume":"109","author":"Agarwal","year":"2019","journal-title":"Biomed. Pharmacother."},{"key":"ref_300","doi-asserted-by":"crossref","unstructured":"Martano, S., De Matteis, V., Cascione, M., and Rinaldi, R. (2022). Inorganic nanomaterials versus polymer-based nanoparticles for overcoming neurodegeneration. Nanomaterials, 12.","DOI":"10.3390\/nano12142337"},{"key":"ref_301","doi-asserted-by":"crossref","first-page":"6490","DOI":"10.1007\/s12035-016-0136-4","article-title":"Anthocyanin-loaded PEG-gold nanoparticles enhanced the neuroprotection of anthocyanins in an A\u03b2 1\u201342 mouse model of Alzheimer\u2019s disease","volume":"54","author":"Ali","year":"2017","journal-title":"Mol. Neurobiol."},{"key":"ref_302","doi-asserted-by":"crossref","first-page":"104604","DOI":"10.1016\/j.arabjc.2023.104604","article-title":"Hibiscus sabdariffa synthesized gold nanoparticles ameliorate aluminum chloride induced memory deficits through inhibition of COX-2\/BACE-1 mRNA expression in rats","volume":"16","author":"Anadozie","year":"2023","journal-title":"Arab. J. Chem."},{"key":"ref_303","doi-asserted-by":"crossref","unstructured":"Li, L., Tan, L., Zhang, Q., Cheng, Y., Liu, Y., Li, R., and Hou, S. (2023). Nose-to-brain delivery of self-assembled curcumin-lactoferrin nanoparticles: Characterization, neuroprotective effect and in vivo pharmacokinetic study. Front. Bioeng. Biotechnol., 11.","DOI":"10.3389\/fbioe.2023.1168408"},{"key":"ref_304","doi-asserted-by":"crossref","first-page":"102534","DOI":"10.1016\/j.jddst.2021.102534","article-title":"Formulation and cognitive evaluation of self-assembled phosphatidylserine-chitosan nanoparticles of lycopene, an innovative technique to lessen STZ-induced oxidative stress: A vital persuader of major neurological diseases","volume":"63","author":"Yusuf","year":"2021","journal-title":"J. Drug Deliv. Sci. Technol."},{"key":"ref_305","doi-asserted-by":"crossref","first-page":"3772","DOI":"10.1021\/acschemneuro.0c00366","article-title":"Piperine-coated gold nanoparticles alleviate paraquat-induced neurotoxicity in Drosophila melanogaster","volume":"11","author":"Srivastav","year":"2020","journal-title":"ACS Chem. Neurosci."},{"key":"ref_306","doi-asserted-by":"crossref","unstructured":"Xue, J., Liu, T., Liu, Y., Jiang, Y., Seshadri, V.D.D., Mohan, S.K., and Ling, L. (2019). Neuroprotective effect of biosynthesised gold nanoparticles synthesised from root extract of Paeonia moutan against Parkinson disease\u2013In vitro & In vivo model. J. Photochem. Photobiol. B Biol., 200.","DOI":"10.1016\/j.jphotobiol.2019.111635"},{"key":"ref_307","doi-asserted-by":"crossref","unstructured":"Ling, L., Jiang, Y., Liu, Y., Li, H., Bari, A., Ullah, R., and Xue, J. (2019). Role of gold nanoparticle from Cinnamomum verum against 1-methyl-4-phenyl-1, 2, 3, 6-tetrahydropyridine (MPTP) induced mice model. J. Photochem. Photobiol. B Biol., 201.","DOI":"10.1016\/j.jphotobiol.2019.111657"},{"key":"ref_308","doi-asserted-by":"crossref","first-page":"299","DOI":"10.2147\/IJN.S347187","article-title":"Nanoparticles in combating neuronal dysregulated signaling pathways: Recent approaches to the nanoformulations of phytochemicals and synthetic drugs against neurodegenerative diseases","volume":"17","author":"Fakhri","year":"2022","journal-title":"Int. J. Nanomed."},{"key":"ref_309","doi-asserted-by":"crossref","unstructured":"Kumar, H., Bhardwaj, K., Nepovimova, E., Ku\u010da, K., Singh Dhanjal, D., Bhardwaj, S., Bhatia, S.K., Verma, R., and Kumar, D. (2020). Antioxidant functionalized nanoparticles: A combat against oxidative stress. Nanomaterials, 10.","DOI":"10.3390\/nano10071334"},{"key":"ref_310","doi-asserted-by":"crossref","unstructured":"Eriksson, P., Tal, A.A., Skallberg, A., Brommesson, C., Hu, Z., Boyd, R.D., Olovsson, W., Fairley, N., Abrikosov, I.A., and Zhang, X. (2018). Cerium oxide nanoparticles with antioxidant capabilities and gadolinium integration for MRI contrast enhancement. Sci. Rep., 8.","DOI":"10.1038\/s41598-018-25390-z"},{"key":"ref_311","doi-asserted-by":"crossref","unstructured":"Gil, D., Rodriguez, J., Ward, B., Vertegel, A., Ivanov, V., and Reukov, V. (2017). Antioxidant activity of SOD and catalase conjugated with nanocrystalline ceria. Bioengineering, 4.","DOI":"10.3390\/bioengineering4010018"},{"key":"ref_312","doi-asserted-by":"crossref","first-page":"6509","DOI":"10.1166\/jnn.2015.10319","article-title":"Zinc oxide nanoparticles suppress LPS-induced NF-\u03baB activation by inducing A20, a negative regulator of NF-\u03baB, in RAW 264.7 macrophages","volume":"15","author":"Kim","year":"2015","journal-title":"J. Nanosci. Nanotechnol."},{"key":"ref_313","doi-asserted-by":"crossref","first-page":"1407","DOI":"10.1177\/0885328216629822","article-title":"Aluminum-doped zinc oxide nanoparticles attenuate the TSLP levels via suppressing caspase-1 in activated mast cells","volume":"30","author":"Kim","year":"2016","journal-title":"J. Biomater. Appl."},{"key":"ref_314","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1152\/physrev.00050.2017","article-title":"Blood-brain barrier: From physiology to disease and back","volume":"99","author":"Sweeney","year":"2019","journal-title":"Physiol. Rev."},{"key":"ref_315","doi-asserted-by":"crossref","first-page":"264","DOI":"10.1016\/j.jconrel.2011.08.017","article-title":"Transport of drugs across the blood\u2013brain barrier by nanoparticles","volume":"161","author":"Wohlfart","year":"2012","journal-title":"J. Control. Release"},{"key":"ref_316","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1080\/17425247.2019.1583205","article-title":"Blood-brain barrier receptors and transporters: An insight on their function and how to exploit them through nanotechnology","volume":"16","author":"Moura","year":"2019","journal-title":"Expert Opin. Drug Deliv."},{"key":"ref_317","doi-asserted-by":"crossref","first-page":"715","DOI":"10.2353\/ajpath.2006.051321","article-title":"The role of type IV collagen and basement membranes in cancer progression and metastasis","volume":"168","author":"Tanjore","year":"2006","journal-title":"Am. J. Pathol."},{"key":"ref_318","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1046\/j.1469-7580.1998.19310001.x","article-title":"The role of laminins in basement membrane function","volume":"193","author":"Aumailley","year":"1998","journal-title":"J. Anat."},{"key":"ref_319","doi-asserted-by":"crossref","first-page":"20230158","DOI":"10.1515\/ntrev-2023-0158","article-title":"Cell type-targeting nanoparticles in treating central nervous system diseases: Challenges and hopes","volume":"12","author":"Guo","year":"2023","journal-title":"Nanotechnol. Rev."}],"container-title":["International Journal of Molecular Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1422-0067\/26\/10\/4707\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,9]],"date-time":"2025-10-09T17:32:45Z","timestamp":1760031165000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1422-0067\/26\/10\/4707"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,5,14]]},"references-count":319,"journal-issue":{"issue":"10","published-online":{"date-parts":[[2025,5]]}},"alternative-id":["ijms26104707"],"URL":"https:\/\/doi.org\/10.3390\/ijms26104707","relation":{},"ISSN":["1422-0067"],"issn-type":[{"value":"1422-0067","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,5,14]]}}}